

Sudden Cardiac Death Compendium

Circulation Research Compendium on Sudden Cardiac Death

The Spectrum of Epidemiology Underlying Sudden Cardiac Death

Sudden Cardiac Death Risk Stratification

Genetics of Sudden Cardiac Death

Mechanisms of Sudden Cardiac Death: Oxidants and Metabolism

Role of Sodium and Calcium Dysregulation in Tachyarrhythmias in Sudden Cardiac Death

Ion Channel Macromolecular Complexes in Cardiomyocytes: Roles in Sudden Cardiac Death

Finding the Rhythm of Sudden Cardiac Death: New Opportunities Using Induced Pluripotent Stem Cell–Derived Cardiomyocytes

Cardiac Innervation and Sudden Cardiac Death

Clinical Management and Prevention of Sudden Cardiac Death

Cardiac Arrest: Resuscitation and Reperfusion

Gordon Tomaselli, Editor

The Spectrum of Epidemiology Underlying Sudden Cardiac Death

Meiso Hayashi, Wataru Shimizu, Christine M. Albert

Abstract: Sudden cardiac death (SCD) from cardiac arrest is a major international public health problem accounting for an estimated 15%–20% of all deaths. Although resuscitation rates are generally improving throughout the world, the majority of individuals who experience a sudden cardiac arrest will not survive. SCD most often develops in older adults with acquired structural heart disease, but it also rarely occurs in the young, where it is more commonly because of inherited disorders. Coronary heart disease is known to be the most common pathology underlying SCD, followed by cardiomyopathies, inherited arrhythmia syndromes, and valvular heart disease. During the past 3 decades, declines in SCD rates have not been as steep as for other causes of coronary heart disease deaths, and there is a growing fraction of SCDs not due to coronary heart disease and ventricular arrhythmias, particularly among certain subsets of the population. The growing heterogeneity of the pathologies and mechanisms underlying SCD present major challenges for SCD prevention, which are magnified further by a frequent lack of recognition of the underlying cardiac condition before death. Multifaceted preventative approaches, which address risk factors in seemingly low-risk and known high-risk populations, will be required to decrease the burden of SCD. In this Compendium, we review the wide-ranging spectrum of epidemiology underlying SCD within both the general population and in high-risk subsets with established cardiac disease placing an emphasis on recent global trends, remaining uncertainties, and potential targeted preventive strategies. (*Circ Res.* 2015;116:1887-1906. DOI: 10.1161/CIRCRESAHA.116.304521.)

Key Words: cardiomyopathies ■ coronary disease ■ death, sudden, cardiac ■ epidemiology

Original received November 16, 2014; revision received February 23, 2015; accepted March 24, 2015. In April 2015, the average time from submission to first decision for all original research papers submitted to *Circulation Research* was 13.84 days.

From the Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan (M.H., W.S.); and Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.M.A.).

Correspondence to Wataru Shimizu, MD, PhD, Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. E-mail wshimizu@nms.ac.jp; or Christine M. Albert, MD, MPH, Division of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave, Boston, MA 02115. E-mail calbert@partners.org

© 2015 American Heart Association, Inc.

Circulation Research is available at <http://circres.ahajournals.org>

DOI: 10.1161/CIRCRESAHA.116.304521

Nonstandard Abbreviations and Acronyms

AF	atrial fibrillation
ARVC	arrhythmogenic right ventricular cardiomyopathy
BrS	Brugada syndrome
CHD	coronary heart disease
EMS	emergency medical service
ERP	early repolarization ECG pattern
HCM	hypertrophic cardiomyopathy
HF	heart failure
ICD	implantable cardioverter defibrillator
LQTS	long-QT syndrome
LVEF	left ventricular ejection fraction
MI	myocardial infarction
NIDCM	non-ischemic dilated cardiomyopathy
OHCA	out of hospital cardiac arrests
PEA	pulseless electrical activity
SCA	sudden cardiac arrest
SCD	sudden cardiac death
VF	ventricular fibrillation
VT	ventricular tachycardia

Sudden Cardiac Death/Sudden Cardiac Arrest: Background, Mechanisms, and Risks

Sudden cardiac death (SCD)/sudden cardiac arrest (SCA) refers to an unexpected death or arrest from a cardiovascular cause that occurs rapidly outside of the hospital or in the emergency room.^{1,2} The presumption based on epidemiologic studies of SCD and SCA survivors is that such rapid deaths are often because of lethal ventricular arrhythmias in the setting of underlying coronary heart disease (CHD).^{3–5} Despite major advances in treatment and prevention of CHD and implantable cardioverter defibrillators (ICDs) for SCD prevention in high-risk patients, SCD remains a major public health problem estimated to account for 15%–20% of all deaths.^{6,7} Reported declines in SCD rates⁸ have not been as steep as for other causes of CHD death,^{9–12} and the reasons for this disparity are not well understood. There may be a growing fraction of SCDs where the underlying cause is not CHD or ventricular arrhythmias,

particularly among certain subsets of the population. In addition, SCD preventive strategies are lacking in low-risk individuals without established heart disease that comprise the largest proportion of SCDs.^{5,13,14} To further reduce the incidence of SCD, preventive strategies need to be tailored to diverse populations at varying levels of risk. In this Compendium, we review the broad spectrum of epidemiology underlying SCD, from common to rare forms, with an emphasis on preventive strategies, recent trends, and unanswered questions.

SCA Incidence: Estimates and Definitions

Estimates on the annual incidence of SCA and SCD vary widely depending on data sources for case ascertainment, definitions used, and methods used for extrapolation of rates.^{15,16} These difficulties in extrapolating SCA and SCD rates are likely magnified further when comparing SCD rates across countries where emergency medical service (EMS) protocols, autopsy rates, and national recording systems vary. The majority of global comparisons (Figure 1) are based on rates of EMS-attended out of hospital cardiac arrests (OHCA), which seem to be much lower in Asia (52.5 per 100 000 person-years) as compared with Europe (86.4 per 100 000 person-years), North America (98.1 per 100 000 person-years), and Australia (111.9 per 100 000 person-years). There also seem to be regional variations within geographic regions.¹⁷ For instance, among 10 regions in North America, rates of EMS attended cardiac arrest range from 159 per 100 000 person-years in Dallas, TX, to 71.8 per 100 000 person-years in Ottawa, ON.

However, the above estimates are crude approximations which at the same time both over- and under-estimate SCA rates. First, EMS is not in attendance for a significant fraction of SCAs, and the proportion of EMS-attended deaths is known to vary significantly across countries. Second, a significant fraction of EMS-attended OHCA are not unexpected nor do they occur in a short time frame from the onset of symptoms. Death certificates are also known to overestimate SCD rates for similar reasons.¹⁸ To obtain a more precise estimate of SCD/SCA, expert panels have advocated for the establishment of precise and uniform definitions of SCD/SCA and to integrate multiple source methods for case ascertainment.^{2,15} Standardized definitions of SCD/SCA have been




Figure 1. Incidence rates of emergency medical service (EMS)-attended out of hospital cardiac arrests (OHCA; A), EMS-treated OHCA (B), and EMS-treated OHCA of presumed cardiac cause (C). Incidence is per 100 000 person-years. Compared with Europe, North America, and Australia, EMS-attended OHCA was lower in Asia, and EMS-treated OHCA of presumed cardiac cause was higher in North America than in other regions. * $P < 0.05$; ** $P < 0.01$; and *** $P < 0.001$. Adapted from Berdowski et al¹⁷ with permission of the publisher. Copyright © 2010, Elsevier. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

proposed, which generally define SCD as an unexpected death without obvious extra-cardiac cause that occurs in association with a witnessed rapid collapse or within 1 hour of the onset of symptoms.^{1,2,19} There are no national surveillance mechanisms to record such characteristics of deaths; and therefore, approximations are based on extrapolations from population-based studies. In prospective studies using standardized definitions and multiple sources of surveillance for case ascertainment in the United States,¹⁸ Netherlands,²⁰ Ireland,²¹ and China,²² SCD rates range from 40 to 100 per 100 000 in the general population,² with rates being lowest in China.²² In individuals aged <35 years, SCD is rare with an incidence of 1 to 3 per 100 000 per year in recent reports.^{23–25}

Even when a strict definition and multiple sources of ascertainment are used, other noncardiac conditions that evolve rapidly such as acute cerebral hemorrhage, aortic rupture, and pulmonary embolism cannot be excluded without a carefully performed autopsy. Autopsy rates are generally low and vary widely across countries with rates as low as 10% of all deaths within the United States²⁶ compared with 23.8% in Finland,²⁷ and the protocols for the performance of autopsies in the cases of suspected SCD vary widely as well, even within regions of countries. These differences in autopsy rates and protocols likely contribute to some of the geographical differences in the incidence and causes of SCD.

SCA Trends in Survival and Underlying Rhythm

Several major advances in cardiopulmonary resuscitation (CPR)²⁸ and postresuscitation care have resulted in improved resuscitation rates from OHCA. In a recent report from the Cardiac Arrest Registry to Enhance Survival, a prospective clinical registry of 70 000 OHCA survivors in the United States, survival rates to hospital discharge increased from 5.7% in 2005 to 8.3% in 2012.²⁹ In Denmark, even greater increases in 30-day survival (3.5%–10.8%) were observed from 2001 to 2010.³⁰ Both in-hospital and prehospital survival rates contribute to these improved outcomes post OHCA. However, even with these improvements, absolute survival rates remain in the ≤10% range.

Although survival rates are higher for OHCA where ventricular fibrillation (VF) is the initial rhythm (21%), the proportion of cases where VF is found at the time of EMS arrival has been declining during the past 3 decades,^{31,32} with a resultant increase in cases where pulseless electrical activity (PEA) and asystole are the initial rhythm.³³ This is an unsettling trend because resuscitation rates are much lower for these rhythms, and we currently have no known strategies for prevention of these deaths.³³ Part of this changing pattern seems to be explained by a concomitant increase in the proportion of arrests occurring in the home,^{4,20,34} where the arrest is less likely to be witnessed. However, even when the arrest is witnessed by a bystander or an automated external defibrillator is applied, VF or pulseless ventricular tachycardia (VT) is less likely to be encountered as the initial rhythm in arrests occurring in the home versus public.⁴ Proposed explanations for the proportional decline in VF as compared with other rhythms include an overall decrease in the prevalence of CHD and an increased

use of β -blockers and ICDs in high-risk patients.^{27,29} At the same time, the population is aging, and advances in medical treatments have resulted in an increased prevalence of end-stage cardiovascular disease as well as other severe comorbidities. These older, sicker patients may be more likely to have arrests in the home setting and to have acute precipitants leading to PEA (ie, respiratory, metabolic, and vascular)^{33,35} and be less likely to sustain VF up to the point of EMS arrival.

Demographics of SCD Victims

The majority of SCDs occur in the adult population, with <1% occurring in individuals aged <35 years.¹⁰ Among adults, the absolute rate of SCD increases markedly with age; however, the proportion of deaths that are sudden seems to be higher in younger age groups.^{5,19,36} There are also recognized differences in SCD incidence by sex and race, which are largely unexplained. Women have a lower incidence of SCD and SCA than men,³⁷ even when one accounts for the prevalence of other predisposing conditions such as CHD, myocardial infarction (MI), and heart failure (HF).^{13,38,39} Women who experience OHCA are on average older, more likely to present with PEA, and experience their arrest at home as compared with men.⁴⁰ These demographics may partially explain why the decline in SCD and OHCA rate has been less pronounced among women as opposed to men in recent years.^{10,12,40} However, women, especially at younger ages,⁴¹ seem to have a higher rate of successful resuscitation and survival from shockable rhythms,⁴⁰ possibly because of favorable effects of smaller body size and estrogen on success of defibrillation and postresuscitation hemodynamics.

With respect to race, black as opposed to white Americans have been documented to have higher rates of OHCA^{42,43} and SCD,^{44,45} as well as poorer rates of survival from cardiac arrest.⁴⁶ Similar to women, blacks of both sexes are more likely to have an unwitnessed arrest or PEA documented at the time of the arrest.^{42,46,47} These unfavorable arrest characteristics do not entirely account for the poorer survival among blacks. Even when limited to OHCA because of VF/VT, national rates of survival to hospital discharge have been documented to be 27% lower among black patients, and much, but not all, of this disparity seems to be explained by black patients receiving treatment at hospitals with worse outcomes.⁴⁸ Blacks may also be less likely to receive prehospital resuscitation efforts in the United States. In 1 recent large cohort study, patients with OHCA in low-income black neighborhoods were less likely to receive bystander-initiated CPR than those in high-income white neighborhoods.⁴⁹

Data are even more limited for other racial and ethnic differences in SCD incidence. Despite having a higher prevalence of cardiac risk factors,⁵⁰ Hispanic Americans may have lower SCD rates than non-Hispanic populations based on limited data from death certificates^{10,51} and coroner evaluations in the United States.⁵² It also seems that the incidence of SCD may be lower among Asian populations in the United States based on death certificate data.¹⁰ Estimates of SCD incidence in longitudinal population-based studies of SCD in China²² and Japan⁵³ are consistently lower than those from studies performed in North America or other regions with predominantly

white populations. These racial differences in SCD/SCA incidence and survival are poorly understood, and further studies performed in large-scale population-based cohort studies of diverse ethnicity are needed to determine the origin of these disparities.

Underlying Pathophysiology of SCD

The epidemiology of SCD is directly related to the pathophysiology that underlies the event. Our knowledge on the predominant pathologies underlying SCD is primarily dependent on autopsy series and cardiac evaluations in cardiac arrest survivors, the detail nature of which may vary significantly among countries. Variation in the meticulous nature of histologic examinations across countries likely influences the reported proportions of pathologic causes of sudden death worldwide. Despite these limitations, it is generally accepted that CHD is the most common cardiac pathology underlying SCD (Figure 2) in adults aged >35 years, particularly among white men where it is responsible for $\approx 70\%$ – 75% of SCDs.^{7,16,20,54} In women, the percentage of SCD and SCA because of CHD seems to be lower. In cardiac arrest survivor series⁵⁵ and SCD autopsy series,⁵⁴ CHD was found in 45%–50% of women versus 80%–90% of men.⁵⁴ The percentage of SCDs with underlying CHD also seems to be lower in blacks versus whites (47% versus 63%) and left ventricular hypertrophy is more common among older black than white SCD victims.⁵⁶ In Japan, CHD is thought to account for a much lower percentage of SCDs,⁵³ although the percentage because of CHD seems to be increasing over time.⁵⁷

Beyond CHD, the causes of SCD are heterogeneous and include cardiomyopathies, valvular heart disease, myocarditis, hypertrophy, and primary electrical heart disease accounting for the remainder. (Figure 2).⁷ On average, a significant cardiac abnormality is not found after clinical evaluation or on autopsy in 5% of SCA cases.^{55,58} This percentage seems to be higher in women, where structurally normal hearts are more commonly encountered.^{54,55,59} In Asians, the primary ion channelopathies are estimated to be responsible for 10% of SCDs.⁶⁰ In young adults and children aged <35 years, CHD accounts for a much smaller proportion of deaths, with hypertrophic cardiomyopathy (HCM), coronary artery anomalies, myocarditis, arrhythmogenic right ventricular cardiomyopathy (ARVC), and primary ion channelopathies accounting for significant proportions.⁶¹

The presumed mechanism underlying an abrupt, unheralded death in these conditions is electrical instability leading to a lethal arrhythmia triggered by ischemia or other arrhythmogenic stimuli resulting in acute hemodynamic collapse. This hypothesis is difficult to prove as most deaths are not monitored, and those that are monitored comprise a highly selected population. Studies in epidemiologic cohorts of men³ and women⁵ from the 1970s to 1990s suggest that 88% to 91% of deaths that occur within 1 hour of symptom onset are arrhythmic in nature. Because VF degenerates to asystole during the course of several minutes, the majority of SCD victims demonstrate asystole or PEA when first examined by rescue teams.⁴⁷ In cases of SCD where there has been a relatively short delay between collapse and the initial determination of rhythm, the proportion of cases with documented ventricular




Figure 2. Causes of sudden cardiac death (SCD) and rates (A) and age of SCD onset in each disease (B). A, Coronary heart disease is the leading cause of SCD, but the rates of baseline heart disease differ between Western countries and Japan. B, SCDs occur in elderly populations in coronary heart disease and valvular heart disease, whereas most SCDs in catecholaminergic polymorphic ventricular tachycardia (CPVT) and long-QT syndrome (LQTS) develop at age <35 years. ARVC indicates arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; NIDCM, non-ischemic dilated cardiomyopathy; and PUFA, polyunsaturated fatty acids.

tachyarrhythmias increases to 75% to 80%.^{4,62,63} However, as mentioned previously, VF is less often and PEA is more commonly encountered in recent OHCA series.³¹ Therefore, a proportion of SCD is likely because of abrupt hemodynamic collapse in the absence of preceding fatal arrhythmia, and this proportion may be growing in the population.

Risk Factors and Predisposing Conditions for SCD in the General Population

The presence of overt structural and primary electrical heart disease is associated with major elevations in SCD risk, and separate risk stratification schema exist for the majority of these disorders, which will be discussed in later sections. However, the majority of SCDs occur among individuals without clinically recognized heart disease.^{5,13,14} Approximately 44%–52% of men and 59%–69% of women who experience SCD will not have had cardiovascular disease diagnosed before the event, and therefore SCD is the first manifestation of heart disease.^{5,13,14} Although the absolute incidence among individuals without apparent heart disease is low, the majority of SCD events take place in this segment of the population. For this segment of the population, current efforts directed at preventing SCD primarily comprised risk factor and lifestyle modification.

CHD Risk Factors

As described above, CHD underlies a significant proportion of SCD, thus risk factors for CHD are associated with SCD risk in the population. Hypertension, diabetes mellitus, hypercholesterolemia, obesity, and smoking have all been associated with elevated risks of SCD among men and women in prospective cohort studies.^{5,13,44,64,65} Diabetes mellitus is a particularly strong risk factor for SCD,^{64,66} even in higher risk populations.^{67,68} Hypertension and resultant left ventricular hypertrophy seem to be particularly important markers of SCD risk in blacks,^{45,56} in whom the prevalence of these conditions is greater.⁶⁹ Smoking confers marked elevations in SCD risk, especially among women.⁵ Importantly, smoking

cessation is associated with a prompt reduction in the elevated risk for SCDs^{70–72} (Figure 3), particularly among individuals who have not yet developed overt CHD.⁷² Serum cholesterol seems to be more strongly related to SCD at younger ages,^{5,38} and a recent meta-analysis of randomized trials suggests that cholesterol lowering with statins may confer modest benefits on SCD incidence.⁷³

Family History of SCD

Several studies have demonstrated a familial predisposition to SCD and VF.^{64,74–76} Three separate case-control studies have demonstrated that a history of SCD among a first-degree relative is an independent risk factor for VF^{75,77} or SCD⁷⁶ in the setting of an acute MI. In the Paris Prospective Study,⁶⁴ parental history of SCD was an independent risk factor for occurrence of SCD (relative risk, 1.80; 95% confidence interval, 1.11–2.88), but was not associated with fatal MI. Conversely, a parental history of fatal MI had no effect on SCD risk. These data in aggregate suggest that genetic or unknown environmental factors responsible for the familial aggregation of SCD or ischemic VF may predispose to fatal arrhythmia as a discrete trait and manifestation of CHD. The consistent associations implicating a family history of arrhythmic death as an independent risk factor for SCD in the general population has led to several studies focused on identifying common genetic variants that predispose to ventricular arrhythmias and SCD in the population.^{78,79}

Diet

Dietary intake and blood-based measures of selected nutrients have been specifically associated with SCD in epidemiologic studies. In observational studies, consuming fish ≈ 1 to 2×/wk has been associated with significant 42%–50% reductions in SCD risk, with minimal impact of risk of non-fatal MI.^{80–82} These inverse associations with SCD were more extreme when marine n-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) were estimated as a proportion of fatty acids from the diet⁸³ or measured directly in blood.^{80,84} These




Figure 3. Reduction in sudden cardiac death (SCD) risk associated with smoking cessation among US middle-aged women. The reference category is current smokers. White diamond, Age-adjusted hazard ratio (HR). Black diamond, Multivariable-adjusted HR. P value for trend <0.0001 in age and multivariable-adjusted models. Adapted from Sandhu et al⁷² with permission of the publisher. Copyright © 2012, Wolters Kluwer Health. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

data in relatively healthy observational cohorts are supportive of experimental data suggesting that n-3 fatty acids may have a selective effect on susceptibility to arrhythmias.⁸⁵ However, randomized trial data in post-MI populations have not been consistently supportive of this hypothesis.^{86–88}

Magnesium intake has also been related to SCD rates. In the Nurses' Health Study, the relative risk of SCD was significantly lower among women in the highest quartile of dietary magnesium intake. The inverse association was stronger for plasma magnesium, where each 0.25 mg/dL (1 SD) increment in plasma magnesium was associated with a 41% reduced risk of SCD.⁸⁹ A similar inverse association between serum magnesium and SCD was also found in the Atherosclerosis Risk in Communities study.⁹⁰ Finally, there are likely additive and interactive effects of these and other nutrients on SCD incidence.⁹¹ Recent data suggest that a Mediterranean-style diet pattern, consisting of higher intake of vegetables, fruits, nuts, whole grains, fish, and low intake of red/processed meat, may also lower SCD risk among women.^{92,93}

Alcohol Intake

The relationship between alcohol intake and SCD is complex. Prospective US cohort studies comprised of individuals consuming small-to-moderate amounts of alcohol^{94–96} have found U-shaped associations between recent alcohol intake and SCD with reduced risks at levels of ½ to 1 drink/d and no reduction at ≥2 drinks/d. Heavy levels of alcohol consumption (>6 drinks/d) have also been associated with increased risk for SCD in other populations.⁹⁷ In contrast, alcohol intake has an inverse linear association with non-fatal MI.⁹⁸ Recently, consuming >1 drink/d was found to be associated with 2-fold elevations in the risk of experiencing VF during acute ST-segment-elevation MI.⁷⁷ These data in aggregate suggest that the favorable effects of alcohol on atherosclerosis and thrombosis may be offset by potential proarrhythmic effects at higher levels of intake.

Atrial fibrillation, Renal Disease, and OSA

Recent data have highlighted the potential link between atrial fibrillation (AF) and SCD. In patients with established AF treated with anticoagulation, SCD accounts for >20% of all deaths.⁹⁹ In recent population-based cohort and case-control studies, patients with AF have on average a 2.5-fold increased risk of SCD¹⁰⁰ or VF^{77,101} as compared with those without AF. The mechanism underlying this elevation in SCD risk is not completely understood, but it does not seem to be entirely dependent on coexisting cardiovascular disease or explained by the use of antiarrhythmic drugs¹⁰¹; however, in a population-based study, much of the excess SCD risk associated with AF could be accounted for by coexisting HF.¹⁰²

Patients with severe chronic kidney disease (CKD) are also at higher risk for SCD, with annualized SCD rates approaching 5.5% in patients undergoing dialysis.¹⁰³ There are also recent data to suggest that individuals with more moderate levels of CKD have a higher risk for SCD as compared with people with normal kidney function.^{68,104} Presumably, some of this could be because of electrolyte shifts and significant degrees of left ventricular hypertrophy observed in these patients. Recent data also suggest that obstructive sleep

apnea¹⁰⁵ and seizure disorders¹⁰⁶ may be contributors to SCD risk in the population. Whether treatment for the above disorders will attenuate the elevated SCD risk is unknown and requires further exploration.

Triggers of SCD

Diurnal/Seasonal Variation

SCD tends to occur more frequently at certain times of the day, week, and year. SCD incidence peaks from 6:00 AM to noon^{107,108} and is highest on Monday and lowest during the weekend.^{109,110} These morning and Monday peaks in SCD rates seem to be blunted by β-blockers,¹¹¹ suggesting that adrenergic triggers may underlie part of these circadian variations. There also seems to be seasonal variability in SCD incidence, with the highest and lowest rates observed in the winter and summer months, respectively, in both hemispheres.^{110,112} These relationships observed in the general population may differ in patients with underlying heart diseases. In patients with ARVC and Brugada syndrome (BrS), ventricular arrhythmias tend to peak in the summer months.^{113,114} These findings suggest that the onset of SCD may be associated with endogenous rhythms and external factors such as activity levels, psychological exposures, sunlight, temperature, and other climatic conditions.^{112,115}

Physical Activity

Most studies,^{65,116–119} but not all,^{120,121} have found protective associations between regular physical activity and SCD or cardiac arrest, particularly for moderate levels of exertion.^{65,68,117–119} It is also well recognized that SCD occurs with a higher than average frequency during or shortly after vigorous exertion. The proportion of exertion-related SCDs varies widely from 3% to 13%^{116,119,121–123} depending on the population surveyed. Case-control and case-crossover analyses have demonstrated that vigorous exertion can trigger cardiac arrest¹¹⁶ and SCD,^{119,121} and this risk seems to be greater in men versus women.^{119,121} Habitual exercise lowers this transient excess risk of SCD; however for men, the risk remains significantly elevated even among those who exercise most frequently.^{119,121}

Despite these risks, the absolute risk of exertion-related SCD is low. Recent population-based estimates on the frequency of exercise-related OHCA and SCD range from 2.1 per 100 000 person-years in the Netherlands¹²² to 0.46 per 100 000 person-years in France.¹²³ The majority of these exertion-related SCD events took place in adults aged >35 years (Figure 4), and the incidence was 15- to 20-fold higher in men than in women.¹²² Even among athletes participating in the same sporting activity, rates of exertion-related SCD remain significantly higher among men.¹²⁴

Psychosocial Determinants

Depression, anxiety, and psychological stress have all been linked to SCD and OHCA risk in diverse populations. Anxiety, particularly phobic anxiety, has been directly associated with SCD, but not nonfatal MI risk, in men¹²⁵ and women.¹²⁶ Depression^{127,128} and other major psychiatric disorders, in particular schizophrenia,¹²⁹ have been associated with higher rates of SCD as well. Potential proarrhythmic properties of




Figure 4. Age distribution of sports-related sudden deaths (SDs) in France. Deaths in the overall population (back) vs young competitive athletes (front). Among the 820 reported sports-related SDs, only 50 cases (6%) occurred in young competitive athletes. Adapted from Marijon et al¹²³ with permission of the publisher. Copyright © 2011, Wolters Kluwer Health. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

antipsychotic or antidepressant medications^{130,131} could underlie part of this apparent excess SCD risk observed in patients with psychiatric disorders. In addition to the chronic effects of psychosocial stress, acute mental stress may act as a trigger for SCD.

Acute increases in the incidence of SCD have been documented in populations experiencing disasters such as earthquakes or wars.^{132–135} On the day of the Northridge earthquake, there was a sharp increase in the number of SCDs related to CHD, which was followed by an unusually low incidence of CHD deaths in the week after the earthquake. In contrast, in the recent Japan earthquake and tsunami, where multiple aftershocks occurred and the level of devastation was high in comparison, the incidence of SCD¹³⁵ and OHCA¹³⁴ was increased for up to 4 weeks after the event, particularly among the elderly, and was significantly associated with level of seismic activity.¹³⁵ These disasters demonstrate how severe emotional stress may precipitate cardiac events in vulnerable and predisposed populations.

Air Pollution

Several studies have examined the impact of short-term air pollution exposures (most often fine particulate matter (PM_{2.5}), carbon monoxide, or oxides of nitrogen), and risk of OHCA.¹³⁶ In studies based in metropolitan areas of Europe,^{137,138} United States,^{139,140} and Australia,¹⁴¹ elevated risks of OHCA have been temporally associated with increased levels of particulate matter. However, other studies from Washington State, United States,¹⁴² and Copenhagen, Denmark,¹⁴³ did not find consistent associations. Long-term exposures to air pollution have been associated with increased mortality from CHD^{144,145} and exposure to roadway pollutants may elevate SCD risk.¹⁴⁶

SCD in the Patient Populations With Structural Heart Disease

Coronary Heart Disease

CHD underlies a significant proportion of SCD, especially in Western countries, and overt CHD is associated with marked increases in SCD risk.¹⁴⁷ In the Framingham Study, pre-existing CHD was associated with 2.8- to 5.3-fold increases in SCD risk,¹³ and women and men have a 4- to 10-fold higher risk of SCD, respectively, after experiencing an MI.^{5,38} The absolute rate of SCD seems to be highest in the first 30 days after MI and decreases gradually with time,^{148,149} although the proportion of patients who die from non-SCD is greater in the first 18 months.¹⁵⁰ The incidence of SCD after MI has declined in parallel with CHD mortality over time,¹⁴⁹ with rates as low as 1%/y in patients receiving optimal medical therapy and revascularization.¹⁵⁰ However, rates remain high in certain subsets of post-MI patients.

There are 3 general settings where SCD occurs in patients with CHD: (1) during or after acute MI, (2) provoked by coronary ischemia without MI, and (3) in the presence of myocardial structural alterations (fibrosis, scar, left ventricular dilatation) secondary to prior MI or chronic ischemia. Only 19% and 38% of cardiac arrest survivors develop a new Q-wave MI and enzymatic evidence of MI, respectively.⁶² The prevalence of acute coronary thrombus or active coronary lesion in autopsy series of SCD varies depending on autopsy protocol and histological techniques, ranging from 19% to 74%.^{151–153} With respect to the type of active lesion found at autopsy, approximately two-third of coronary thrombi are organizing, and late stage lesions or coronary erosions are more commonly encountered in women.¹⁵⁴ In most series,^{152,155,156} stable plaques and chronic changes alone are found in ≈50%

of SCD victims with CHD on autopsy. From these data, it seems that plaque rupture with or without associated thrombosis and MI is present in some, but not all, patients with CHD at the time of SCD.

The potential underlying mechanism precipitating SCD also differs depending on the setting in which it occurs and the chronicity of disease. The 2 most common mechanisms are thought to be polymorphic VT/VF precipitated by acute ischemia and infarction and monomorphic VT degenerating to VF arising from a reentrant circuit within or surrounding a myocardial scar. In addition to these primary arrhythmic causes, a significant proportion of SCDs in the post-MI population seem to be because of nonarrhythmic causes such as myocardial rupture and extensive reinfarction, and this percentage seems to be highest within the first month after MI.¹⁵⁷ In patients with end-stage ischemic cardiomyopathy, other modes of death such as acute pump failure and respiratory arrest resulting in PEA, or primary bradyarrhythmias comprise a significant proportion of SCD as well.¹⁵⁸

Risk Factors for SCD in Patients With Established CHD

Left ventricular systolic dysfunction and severity of HF symptoms are currently the strongest predictors of SCD risk among patients with prior MI and ischemic cardiomyopathy.^{158–160} After MI, mortality risk increases gradually until the left ventricular ejection fraction (LVEF) declines to 40%, and then exponentially increases as LVEF decreases further.¹⁶¹ SCD rates reach 10% during a median follow-up of ≈ 2 years among patients with LVEF $<30\%$ and CHF in clinical trials.^{148,162} Based on randomized clinical trials performed in populations with low LVEFs and CHF,^{162–164} ICD therapy is recommended for patients with ischemic dilated cardiomyopathy, prior MI, New York Heart Association class II and III HF, and LVEF $\leq 35\%$.¹⁶⁵ In contrast, ICD therapy does not reduce mortality in the early post-MI period (within 40 days),^{166,167} possibly because of a predominance of nonarrhythmic causes of death during this time window.¹⁵⁷

Stratifying SCD risk based solely on LVEF and degree of systolic HF has 2 major well-recognized limitations. First, LVEF and New York Heart Association class are both strongly associated with other modes of cardiovascular death,^{148,168} and patients with the greatest functional impairment secondary to systolic HF and lowest LVEF are more likely to die from HF as opposed to SCD.¹⁵⁸ The inability of these clinical markers to discriminate SCD risk from other competing causes of death has important clinical implications. In a recent prospective study series of 1100 patients with systolic dysfunction,¹⁶⁹ patients with CHD who received primary prevention ICDs on the basis of LVEF and CHF were more likely to die than to experience an appropriate ICD therapy from their device. Second, the majority of patients who experience a SCA or SCD do not seem to have LV systolic dysfunction and clinical HF preceding death.^{7,19} In a prospective registry of cardiac arrests in the Netherlands, only 26% of SCAs with heart disease had HF before death, and only 19% of patients had an LVEF $\leq 30\%$.¹⁴ In a more contemporary cohort in Multnomah County, Oregon, one-third of SCAs who had an echocardiogram before death had an LVEF $<35\%$.¹⁷⁰

In addition to LVEF and CHF, other potential markers of increased SCD risk in patients with CHD include sustained

VT induced at electrophysiology study, left ventricular scar size and heterogeneity on cardiac magnetic resonance, T-wave alternans, markers of autonomic function such as baroreflex sensitivity and impaired heart rate turbulence, and conventional ECG measures such as left bundle branch block, QRS duration, left ventricular hypertrophy, and QT interval.^{161,171–173} To date, only inducible sustained VT at electrophysiology study has been proven in a randomized clinical trial to identify individuals at a higher risk of SCA versus non-SCA.¹⁷¹ However, the sensitivity of this test in isolation is inadequate to guide ICD therapy, especially in patients with LVEF $<30\%$.^{161,171} Recently, sustained VT at electrophysiology study was also found to be effective at stratifying arrhythmic death risk among patients with LVEF $<35\%$ in the early post-MI period.¹⁷⁴

Risk Factors for SCD in Patients With Preserved LVEF

Although the incidence of SCD is lower in patients with HF with preserved LVEF as compared with those with reduced LVEF, the ratio of SCD to progressive HF deaths is higher, with SCD comprising 11% to 28% of all deaths.^{175–177} Relatively little is known about SCD risk prediction in patients with CHD with preserved LVEFs. Prior history of MI, HF, and history of diabetes mellitus are consistent risk factors for SCD in this population.^{178,179} Other potential clinical risk factors identified in these populations include male sex, AF, physical inactivity, left bundle branch block on ECG, NT-proBNP (N-terminal pro-B type natriuretic peptide) levels, and severity of coronary artery disease.^{68,178,179}

Cardiomyopathies

Next to CHD, non-ischemic cardiomyopathies are the second most frequent cause of SCD in the United States and European countries, which account for $\approx 10\%$ to 15% (Figure 2).^{7,10,18} Furthermore, the prevalence of cardiomyopathies in young autopsied SCD victims aged ≤ 35 years is higher and is reported to be 15% to 30% .^{24,25,180,181} However, non-ischemic cardiomyopathies are more frequently observed as a cause of SCD in Japan ($\approx 30\%$ – 35% of SCD victims).¹⁸² The 3 major causally distinct cardiomyopathies are non-ischemic dilated cardiomyopathy (NIDCM), HCM, and ARVC.

Non-Ischemic Dilated Cardiomyopathy

NIDCM has an estimated prevalence of 1:2500¹⁸³ and is defined by the presence of LV dilatation and LV systolic dysfunction in the absence of abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment.¹⁸⁴ Causes of NIDCM include gene mutations, myocarditis caused by viral, bacterial, fungal, or parasitic infections, toxicity because of alcohol, chemotherapeutic agents, metals, and autoimmune and systemic disorders. However, the majority of cases remain unexplained despite a thorough evaluation. Inherited NIDCM is reported to occur in $\leq 40\%$ of cases, mostly in an autosomal dominant fashion.¹⁸⁵ To date, mutations in >40 genes have been reported, in which *TTN*, *MYH7*, *TNNT2*, and *LMNA* are the most frequently identified, encoding titin, myosin heavy chain, cardiac troponin T (all in sarcomere), and lamin A/C (in nuclear envelope), respectively.¹⁸⁵

Prior episodes of sustained VT, history of syncope, reduced LVEF, HF, and family history of SCD are the primary

risk factors used to identify patients at a sufficiently high enough SCD risk to warrant ICD therapy.¹⁸⁶ Two primary prevention randomized trials of ICD therapy^{187,188} included NIDCM patients with LVEF of $\leq 35\%$ and HF symptoms (New York Heart Association I–III) and demonstrated significant reductions in the SCD rate in patients with NIDCM (hazard ratio of 0.20¹⁸⁸ and 0.34¹⁸⁹) and reductions in total mortality when combined in meta-analysis.¹⁸⁹ However, as in patients with ischemic cardiomyopathy, LVEF has a low sensitivity and specificity for predicting SCD and more specific markers are needed.¹⁹⁰ Recently, midwall fibrosis detected by late gadolinium enhancement cardiac magnetic resonance was demonstrated to improve SCD risk prediction beyond LVEF in a large study of patients with NIDCM.¹⁹¹

Hypertrophic Cardiomyopathy

HCM, defined by increased LV wall thickness not solely explained by abnormal loading conditions, is considered the most common inherited cardiac disease with an estimated prevalence of 1:500 in the general population.¹⁹² In adult patients, the clinical diagnosis of HCM is made by cardiac imaging showing a left ventricular wall thickness of ≥ 15 mm in ≥ 1 segments. HCM can be present with lesser degrees of the wall thickening (13–14 mm), but other features of HCM, such as a family history, noncardiac symptoms and signs, ECG abnormalities, and abnormalities on multimodality cardiac imaging, are required to support the diagnosis.¹⁹³ To date, >1500 mutations in >11 genes encoding components of the sarcomere or adjacent Z-disc have been identified, with the most common encoding β -myosin heavy chain and myosin binding protein C.^{192,193}

The annual incidence of cardiovascular death in HCM is $\approx 0.5\%$ to 2% in contemporary series, and SCD from a lethal ventricular arrhythmia remains one of the common modes of death.^{192,193} SCD is more likely to occur in young patients (<30 years) and is uncommon in older patients (>60 years).¹⁹² Established risk factors for SCD in patients with HCM include a history of unexplained syncope, family history of SCD, a maximal left ventricular wall thickness of ≥ 30 mm, repetitive non-sustained VT, and abnormal blood pressure response to exercise.¹⁹² According to the American College of Cardiology Foundation and American Heart Association guidelines, the presence of ≥ 1 of these risk factors can be used to select patients for primary prevention ICD placement.¹⁹⁴ The most recent European Society of Cardiology guidelines¹⁹³ recommend the use of a prediction model, which incorporates absolute risk and individual effect sizes of the above and other SCD risk factors (Figure 5)¹⁹⁵ at 1- to 2-year intervals. Implantation of an ICD is recommended in patients with an estimated 5-year SCD risk of $\geq 6\%$ and a life expectancy of >1 year (class IIa).

Arrhythmogenic Right Ventricular Cardiomyopathy

ARVC is a genetically determined heart muscle disorder characterized by fibrofatty replacement of the right ventricular myocardium.¹⁹⁶ As the disease progresses, the left ventricle may also become involved. The estimated prevalence of ARVC is 1: 2000 to 5000,¹⁹⁷ and $\leq 60\%$ of the patients have a mutation with an autosomal dominant trait and incomplete penetrance.¹⁹⁸ Among ≈ 15 genes have been reported to cause

$$\text{Probability of SCD at 5 years} = 1 - 0.998^{\text{exp(Prognostic Index)}}$$

$$\begin{aligned} \text{Prognostic Index} = & 0.15939858 \times \text{Maximal wall thickness (mm)} \\ & - 0.00294271 \times \text{Maximal wall thickness}^2 \text{ (mm}^2\text{)} \\ & + 0.0259082 \times \text{Left atrial diameter (mm)} \\ & + 0.00446131 \times \text{Maximal LVOT gradient (mmHg)} \\ & + 0.4583082 \times \text{Family history of SCD} \\ & + 0.82639195 \times \text{NSVT} \\ & + 0.71650361 \times \text{Unexplained syncope} \\ & - 0.01799934 \times \text{Age at clinical evaluation (years)} \end{aligned}$$

Figure 5. Sudden cardiac death (SCD) risk prediction model for patients with hypertrophic cardiomyopathy. A web-based risk calculator is provided on the website of European Society of Cardiology (<http://www.doc2do.com/hcm/webHCM.html>). LVOT indicates left ventricular outflow tract; and NSVT, non-sustained ventricular tachycardia. Adapted from O'Mahony et al¹⁹⁵ and Elliott et al¹⁹³ with permission of the publisher. Copyrights © 2014, Oxford University Press. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

ARVC, mutations in genes encoding components of cardiac desmosomes (plakophilin 2, desmoglein 2, and desmoplakin) are most frequently identified.¹⁹⁸ The 2010 Task Force diagnostic criteria for ARVC¹⁹⁶ consist of major and minor findings in 6 different categories: (1) structural alterations, (2) tissue characterization, (3) repolarization abnormalities, (4) depolarization abnormalities, (5) arrhythmias, and (6) family history including genetic testing.

SCD is a common cause of death in patients with ARVC especially in those in the fourth decade of life or younger, and it may be the first arrhythmic event in up to 50% of cases.^{199,200} Several observational studies^{201–204} showed that the annual rate of death or VF in patients treated by ICDs was 1.5% to 4%, and predictors of appropriate ICD therapy include a history of a cardiac arrest or VT with hemodynamic compromise, younger age, LV involvement, unexplained syncope, presence of non-sustained VT, and inducibility during electrophysiology study.^{201,204} Current American College of Cardiology Foundation/ American Heart Association/Heart Rhythm Society guidelines¹⁸⁶ recommend the prophylactic use of an ICD in those who have ≥ 1 risk factors for SCD (class IIa).

Valvular Heart Disease

Valvular heart disease is reported to be the cause of death in 1% to 5% of the SCD victims (Figure 2).^{10,18,205} Even after surgical procedures, SCD occurs in 15% to 30% of patients, accounting for 0.2% to 0.9%/y and is most commonly triggered by ventricular arrhythmias.²⁰⁶ Patients with aortic stenosis are at the highest risk of SCD after valve replacement, particularly within 2 years.²⁰⁶ Before valve replacement, asymptomatic patients with severe AS have annual SCD rates of 1%–3%,^{207,208} and recent observational data suggest that this risk may be lowered by early surgery.²⁰⁹ The role of mitral valve prolapse in SCD is controversial. The majority of mitral valve prolapse is thought to be benign, but there are certain characteristics such as leaflet thickness, redundancy, and increased LV diameter that seem to be associated with higher risk,²¹⁰ and recent data suggest that women with bileaflet prolapse and complex

ventricular ectopy may be at particular risk.²¹¹ Overall, data on SCD risk stratification and appropriate use of ICDs in patients with valvular disease are scarce and further studies in this at-risk subgroup of patients are needed.

SCD in the Absence of Structural Heart Disease

Autopsy-Negative SCD/Sudden Unexplained Death

Autopsy-negative sudden death is more commonly reported in younger individuals. Autopsy series from Ireland²⁴ and Sydney¹⁸¹ reported that 27% to 29% of sudden arrhythmic deaths in individuals aged <35 years had no demonstrable structural heart disease on autopsy. In a Danish nationwide study of SCD,²³ this proportion was even higher (43%). However, when detailed histologic examinations are performed, the percentage of autopsy-negative SCD is much lower. In a prospective study of 273 consecutive SCD cases aged 1 to 35 years in Italy,¹⁸⁰ detailed histologic examination identified concealed pathologic substrates, such as focal myocarditis, regional ARVC, and conduction system abnormalities in 60 of 76 cases without macroscopic evidence for structural heart disease. After histologic exam, only 16 (6%) had no detectable abnormalities. Although discordances in the frequency of the autopsy-negative SCDs could be because of differences in regional genetic background, it is likely that the frequency of autopsy-negative cases would decrease if more detailed histologic examinations were carried out in all SCD victims.

Among patients with autopsy negative SCD, ~50% will have inherited arrhythmic syndromes,^{212,213} such as, long-QT syndrome (LQTS), BrS, catecholaminergic polymorphic VT, and early repolarization syndrome. Even when structural abnormalities of uncertain significance are found, inherited arrhythmic syndromes seem to underlie a significant fraction of SCDs.²¹⁴ Taken together, these findings suggest that substantial numbers of SCD may be attributable to inherited arrhythmic syndromes in the young. Performing molecular autopsies in cases with autopsy-negative SCD and cascade screening of families is important to establish the cause of death and to identify relatives potentially at high SCD risk. In cases of sudden unexplained death, where a diagnosis is not made either by antemortem or postmortem analysis, genetic testing of family members reveals a possible disease-causing mutation in 31% of families, and inherited arrhythmic syndromes comprise 30% of these mutations.²¹⁵

Inherited Arrhythmic Disorders and Their Epidemiology

Long-QT Syndrome

Congenital LQTS is a hereditary disorder, characterized by delayed myocardial repolarization resulting in prolongation of the QT interval on 12-lead ECG and predisposition to torsade de pointes, which can result in SCD.^{216,217} Approximately 75% of patients with LQTS and 95% of genotype-positive LQTS will have a mutation in genes encoding the slow component (*KCNQ1*, LQT1) and the rapid component (*KCNH2*, LQT2) of the delayed rectifier potassium current and the cardiac sodium channel (*SCN5A*, LQT3).^{218,219} Conversely, it is estimated

that 25% to 35% of genetically affected patients have a normal or borderline QTc at rest,^{219,220} requiring exercise or a catecholamine infusion to disclose the masked QT interval.^{217,220,221} To directly estimate the prevalence of LQTS, Schwartz et al²²² performed 12-lead ECGs in 43 080 white infants. Prolonged QTc intervals of 451 to 460, 461 to 470, and >470 ms were observed in 177 (0.41%), 28 (0.06%), and 31 (0.07%) infants, respectively. Of these, 17 of 43 080 infants were found to be affected by LQTS on the basis of genetic testing and further clinical evaluation, indicating a prevalence among whites of 1:2534. Extrapolating these results to the nongenotyped infants, the authors estimated the prevalence of LQTS was closer to 1:2000.²²²

The estimated incidence of cardiac arrest or SCD before the age of 40 years in untreated patients is estimated to be 0.30%/y, 0.60%/y, and 0.56%/y in LQT1, LQT2, and LQT3, respectively.²¹⁹ Most arrhythmic events developed during exercise or emotional stress in LQT1, at rest or with sudden noises in LQT2, and at rest or during sleep in LQT3.²²³ Other risk factors for arrhythmic events in LQTS include prior history of syncope, significant QTc prolongation,^{219,224} and location and number of mutations.^{219,224–227} β -Blockers remain the mainstay of therapy for the majority of these patients, and ICDs are generally reserved for patients who have experienced a cardiac arrest.²²⁸

Brugada Syndrome

BrS was first described in 1992²²⁹ and is thought to underlie, to a certain extent, the mystery of unexpected nocturnal death, which is colloquially called Pokkuri in Japan, Lai Tai in Thailand, and Bangungut in the Philippines.²³⁰ BrS is a primary electrical disorder affecting middle-aged men with their first arrhythmic event typically developing during sleep at a mean age of 40 years.²³¹ The clinical phenotype is 8 to 10× more prevalent in men than in women, which is attributable, at least in part, to the higher testosterone level in men.²³² Twelve-lead ECGs at rest are characterized by a coved type ST-segment and J point elevation of ≥ 2 mm (0.2 mV) followed by a negative T wave in the right precordial leads (V1–3), which is referred to as a type 1 Brugada ECG.²³¹

In the 2013 Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society expert consensus statement,²²⁸ BrS is diagnosed when a type 1 ST-segment elevation is observed either spontaneously or after the administration of a sodium channel blocking agent in at least 1 right precordial lead (V1 and V2), which is placed in a standard or a superior position; in which case, documentation of VT/VF, clinical symptoms, or a family history is no longer necessary. Table 1 displays the reported prevalence of a type 1 Brugada ECG across population-based studies. The prevalence of the type 1 ECG pattern in adults is greatest in Japan,^{233,234} the Philippines,²³⁵ and among Japanese-Americans in North America²³⁶ (0.15%–0.27% [1:350–700]). Rates in Europe^{237–239} (0%–0.017% [$<1:5000$]) and North America^{240,241} (0.005%–0.1% [1:1000–20 000]) seem to be lower. These estimates of BrS do not account for temporal variability of the ECG morphology²³³ or patients who exhibit type 1 ECG only in the superior lead positions or after drug-provocation.²²⁸

Table 1. Prevalence of a Type 1 Brugada ECG* in the Population Studies

Country	Authors	Year Published	Individuals Screened, n	Male Sex, %	Mean Age or Range of Age, y	Type 1 ECG, n (%)
Europe						
Finland	Junttila et al ²⁶⁴	2004	2479	100	18–30	0
Greece	Letsas et al ²³⁷	2007	11 488	58	15–98	2 (0.017)
Italy	Gallagher et al ²³⁸	2008	12 012	91	30±9	2 (0.017)
Germany	Sinner et al ²⁶⁵	2009	4149	49	51±14	0
Denmark	Pecini et al ²³⁹	2010	18 974	45†	52±12*	0
North America						
Canada	Lee et al ²⁴¹	2005	3983	100	31	4 (0.100)
United States (Japanese–American)	Ito et al ²³⁶	2006	8006	100	45–68	12 (0.150)
United States	Patel et al ²⁴⁰	2009	162 590	65	Not described	8 (0.005)
Asia						
Japan	Sakabe et al ²³³	2003	3339	79	>18	5 (0.150)‡
Japan	Yamakawa et al ²⁶⁶	2004	20 387	51	10	1 (0.005)
Japan	Oe et al ²⁶⁷	2005	21 944	51	7	1 (0.005)
Japan	Tsuji et al ²³⁴	2008	13 904	27	58±10	37 (0.266)
Philippines	Gervacio-Domingo et al ²³⁵	2008	3907	Not described	≥20	7 (0.179)
Taiwan	Juang et al	2011	20 562	39	49±21	1 (0.005)
Korea	Uhm et al	2011	10 867	100	21±5	0

*Studies including patients with a coved type ECG and J point amplitude ≥ 0.1 mV were excluded.

†In the first examination.

‡Those with a continuous type 1 ECG.

The primary risk factors for SCD in type 1 BrS are prior history of syncope or aborted SCD. In recently published multicenter registry studies,^{242–244} the incidence of the cardiac events (SCD, VF, and appropriate ICD shocks) in type I BrS ranged from 7.7% to 10.2%/y, 0.6%–3.0%/y, and 0.5%–0.8%/y in those with a history of aborted SCD because of VF, syncope episodes, and no symptoms, respectively.

Catecholaminergic Polymorphic VT

Catecholaminergic polymorphic VT is a familial arrhythmogenic disorder characterized by polymorphic ventricular tachyarrhythmias or bidirectional VT induced by physical or emotional stress.²⁴⁵ The patients show no detectable cardiac morphological abnormalities, and the ECG is normal except for a lower heart rate at rest.^{245,246} The affected patients usually develop arrhythmic events (syncope, aborted cardiac arrest, or SCD) during adrenergic activity in the first or second decade of life,^{245,247–249} and the clinical course is considered to be highly malignant. Without proper treatment such as β -blockers, flecainide, and ICDs,^{245–251} mortality reaches >30% by the age of 30 years²⁵⁰ and the estimated 8-year fatal or aborted SCA event rate after the diagnosis is 13%.²⁴⁷ The population prevalence of catecholaminergic polymorphic VT is difficult to estimate because it cannot be detected on resting 12-lead ECG, but is projected to be $\approx 1:10\,000$.²²⁸

Early Repolarization Syndrome

An early repolarization ECG pattern (ERP), which consists of a J wave elevation ≥ 0.1 mV, either notched or slurred,

accompanied by an ST-segment elevation, has long been considered to be a benign finding and unrelated to serious cardiac events.^{252,253} This notion has recently been challenged by studies demonstrating that an ERP in the inferior and lateral leads is more commonly found in patients with idiopathic VF as compared with controls,^{254,255} raising the possibility that the ERP may be a marker of an arrhythmogenic substrate. Considering these data, a recent expert consensus panel defined ERP as the presence of J point elevation ≥ 0.1 mV in ≥ 2 contiguous inferior and lateral leads, and early repolarization syndrome is diagnosed in the presence of ERP in a patient resuscitated from otherwise unexplained VF/polymorphic VT or autopsy negative SCD victim with a previous ECG demonstrating ERP.²²⁸

The question of whether an ERP on resting ECG confers an increased risk of SCD in the general population has been examined in several population-based studies,^{253,256–261} which are summarized in Table 2. The definition of ERP varies widely between these studies. In some studies, ERP had to be present in the inferior and lateral leads,^{256,257,260} but others considered J point ST elevations in all body surface leads to be ERP.^{253,258,259,261} Prevalence estimates in these studies range from 1% to 24% and 0.6% to 6.4% for J point elevation of ≥ 0.1 and 0.2 mV, respectively. Notwithstanding these differences in methodology, ERP is reported to be more prevalent in younger age groups, men, or individuals of African descent.^{258,259,262} The majority of European studies^{256,257} and Japanese studies^{260,261}

Table 2. Prevalence of Early Repolarization ECGs and Their Prognosis in the Population Studies

Country	Authors	Year Published	Position of ERP	Individuals Screened, n	Male Sex, %	Mean Age at Baseline, y	J Point Elevation, n (%)		Mean Follow-Up Period, y	RR of Death According to the ERP	
							≥0.1 mV	≥0.2 mV		Cardiac	Sudden or Arrhythmic
Europe											
Finland	Tikkanen et al ²⁵⁶	2009	Inf or lat	10 864	52	44±8	630 (5.8)	67 (0.6)	30±11	1.28* in inf 1.34* in lat	1.43* in inf 0.75 in lat
Germany	Sinner et al ²⁵⁷	2010	Inf or lat	6213	49	52±10	812 (13.1)	Not described	19	3.44*	Not described
France	Rollin et al ²⁶⁸	2012	Inf or lat	1161	52	50±9	159 (13.7)	74 (6.4)	14±2	5.28* in inf 6.27* in lat†	Not described
North America											
United States	Klatsky et al ²⁵³	2003	All	73 088	44	37±13	670 (0.9)	494 (0.7)	14	0.8†	Not described
United States	Uberoi et al ²⁶⁹	2011	Inf or lat	29 281	87	55±15	664 (2.3)	0	8±4	1.73 in inf 0.83 in lat†	Not described
United States	Olson et al ²⁵⁸	2011	All	15 141	44	54±6	1866 (12.3)	Not described	17±4	Not described	1.23 in all 2.03* in whites
United States	Ilkhanoff et al ²⁵⁹	2014	All	5039	46	25	1249 (20.9)‡	Not described	23	0.96†	Not described
Asia											
Japan	Haruta et al ²⁶⁰	2011	Inf or lat	5976	44	Not described	1429 (23.9)	Not described	24±15	0.75*	1.83*
Japan	Hisamatsu et al ²⁶¹	2013	All§	7630	41	52	264 (3.5)	Not described	15	2.54*	Not described

ERP indicates early repolarization pattern; Inf, inferior leads; Lat, lateral leads; and RR, relative risk.

*Statistically significant.

†For the cardiovascular death.

‡At baseline.

§≥0.2 mV in anterior leads.

found significant associations between the ERP and cardiac or sudden arrhythmic death, whereas studies conducted in the United States generally did not.^{253,258,259} One US study suggested that the association between ERP and SCD may be limited to women and white individuals.²⁵⁸ These results suggest that there may be an ethnic, racial, and sex differences in the relationship between the ERP and SCD.

It is important to note that the calculated relative risks for sudden arrhythmic death associated with a J point elevation of 0.1 mV are modest (Table 2) and the absolute risk of arrhythmic death in asymptomatic individuals with the ERP on ECG is extremely low.²⁵⁵ Three-fold elevations in sudden/arrhythmic death have been observed when ERP is more strictly defined as a J point elevation of >0.2 mV associated with horizontal/descending ST segment limited to the inferior leads.^{256,263} However, this pattern was only noted in 0.3% of the population.²⁶³

Conclusions

SCD is a major public health problem all over the world, and although resuscitation rates are improving, the majority of individuals who experience SCA will not survive, and often the underlying cardiac condition is not recognized before death. Behind these tragic events, there are various causes, risks,

and predisposing conditions, which differ in the prevalence according to region, age, ethnicity, race, and sex. As such, a multifaceted approach, which addresses risk factors both in high- and low-risk populations, will be required to decrease the burden of SCD. Population-wide approaches as well as improved identification of high-risk individuals who will benefit from ICDs will be crucial to prevent SCD events and improve patient outcomes. Although substantial progress has been made in this field, further studies addressing SCD prevention across the whole spectrum of disorders, from CHD in the general population to the rarer inherited disorders, are warranted to address many remaining uncertainties on the multitude of factors, which underlie susceptibility to SCD.

Sources of Funding

Dr Shimizu was supported in part by Grants from the Ministry of Health, Labor and Welfare of Japan for Clinical Research on Intractable Diseases (H24-033, H26-040) and a Nippon Medical School Grant-in-Aid for Medical Research. Dr Albert is supported by grants received from the St. Jude Medical and the National Heart, Lung, and Blood Institute (HL091069, HL11690) and an Established Investigator Award from the American Heart Association.

Disclosures

None.

References

- Lopshire JC, Zipes DP. Sudden cardiac death: better understanding of risks, mechanisms, and treatment. *Circulation*. 2006;114:1134–1136. doi: 10.1161/CIRCULATIONAHA.106.647933.
- Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. *Circulation*. 2010;122:2335–2348. doi: 10.1161/CIRCULATIONAHA.110.976092.
- Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. *Circulation*. 1982;65:457–464.
- Weisfeldt ML, Everson-Stewart S, Sitlani C, Rea T, Aufderheide TP, Atkins DL, Bigham B, Brooks SC, Foerster C, Gray R, Ornato JP, Powell J, Kudenchuk PJ, Morrison LJ; Resuscitation Outcomes Consortium Investigators. Ventricular tachyarrhythmias after cardiac arrest in public versus at home. *N Engl J Med*. 2011;364:313–321. doi: 10.1056/NEJMoa1010663.
- Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, Stampfer MJ, Manson JE. Prospective study of sudden cardiac death among women in the United States. *Circulation*. 2003;107:2096–2101. doi: 10.1161/01.CIR.0000065223.21530.11.
- Gillum RF. Geographic variation in sudden coronary death. *Am Heart J*. 1990;119:380–389.
- Myerburg RJ, Castellanos A. Sudden cardiac death. In: Zipes DP, Jalife J, eds. *Cardiac electrophysiology: From cell to bedside*. 5th edn. Philadelphia, PA: Saunders Elsevier; 2009:797–808.
- Niemeijer MN, van den Berg ME, Leening MJG, Hofman A, Franco OH, Deckers JW, Heeringa J, Rijnbeek PR, Stricker BH, Eijgelsheim M. Declining incidence of sudden cardiac death from 1990–2010 in a general middle-aged and elderly population: The rotterdam study. *Heart Rhythm*. 2015;12:123–129.
- Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. *Circulation*. 2004;110:522–527. doi: 10.1161/01.CIR.0000136993.34344.41.
- Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. *Circulation*. 2001;104:2158–2163.
- Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). *Circulation*. 2011;123:46–52. doi: 10.1161/CIRCULATIONAHA.110.964999.
- Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in deaths from cardiovascular diseases: a 25-year community study. *Circulation*. 2006;113:2285–2292. doi: 10.1161/CIRCULATIONAHA.105.590463.
- Cupples LA, Gagnon DR, Kannel WB. Long- and short-term risk of sudden coronary death. *Circulation*. 1992;85:111–118.
- Gorgels AP, Gijbbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest—the relevance of heart failure. The Maastricht Circulatory Arrest Registry. *Eur Heart J*. 2003;24:1204–1209.
- Kong MH, Fonarow GC, Peterson ED, Curtis AB, Hernandez AF, Sanders GD, Thomas KL, Hayes DL, Al-Khatib SM. Systematic review of the incidence of sudden cardiac death in the United States. *J Am Coll Cardiol*. 2011;57:794–801. doi: 10.1016/j.jacc.2010.09.064.
- Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. *Circulation*. 2012;125:1043–1052. doi: 10.1161/CIRCULATIONAHA.111.023846.
- Berdowski J, Berg RA, Tijssen JG, Koster RW. Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. *Resuscitation*. 2010;81:1479–1487. doi: 10.1016/j.resuscitation.2010.08.006.
- Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, Ilias N, Vickers C, Dogra V, Daya M, Kron J, Zheng ZJ, Mensah G, McAnulty J. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. *J Am Coll Cardiol*. 2004;44:1268–1275. doi: 10.1016/j.jacc.2004.06.029.
- Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation*. 2006;114:e385–e484. doi: 10.1161/CIRCULATIONAHA.106.178233.
- de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. *J Am Coll Cardiol*. 1997;30:1500–1505.
- Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, Crowley J. Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. *Eur Heart J*. 2008;29:1418–1423. doi: 10.1093/eurheartj/ehn155.
- Hua W, Zhang LF, Wu YF, Liu XQ, Guo DS, Zhou HL, Gou ZP, Zhao LC, Niu HX, Chen KP, Mai JZ, Chu LN, Zhang S. Incidence of sudden cardiac death in China: analysis of 4 regional populations. *J Am Coll Cardiol*. 2009;54:1110–1118. doi: 10.1016/j.jacc.2009.06.016.
- Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, Bundgaard H, Svendsen JH, Haunsø S, Tfelt-Hansen J. Nationwide study of sudden cardiac death in persons aged 1–35 years. *Eur Heart J*. 2011;32:983–990. doi: 10.1093/eurheartj/ehq428.
- Margey R, Roy A, Tobin S, O'Keane CJ, McGorrian C, Morris V, Jennings S, Galvin J. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. *Europace*. 2011;13:1411–1418. doi: 10.1093/europace/eur161.
- Papadakis M, Sharma S, Cox S, Sheppard MN, Panoulas VF, Behr ER. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. *Europace*. 2009;11:1353–1358. doi: 10.1093/europace/eup229.
- Shojania KG, Burton EC. The vanishing nonforensic autopsy. *N Engl J Med*. 2008;358:873–875. doi: 10.1056/NEJMp0707996.
- Lunetta P, Lounamaa A, Sihvonen S. Surveillance of injury-related deaths: medicolegal autopsy rates and trends in Finland. *Inj Prev*. 2007;13:282–284. doi: 10.1136/ip.2006.012922.
- Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122:S640–S656. doi: 10.1161/CIRCULATIONAHA.110.970889.
- Chan PS, McNally B, Tang F, Kellermann A; CARES Surveillance Group. Recent trends in survival from out-of-hospital cardiac arrest in the United States. *Circulation*. 2014;130:1876–1882. doi: 10.1161/CIRCULATIONAHA.114.009711.
- Wissenberg M, Lippert FK, Folke F, et al. Association of national initiatives to improve cardiac arrest management with rates of bystander intervention and patient survival after out-of-hospital cardiac arrest. *JAMA*. 2013;310:1377–1384. doi: 10.1001/jama.2013.278483.
- Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980–2000. *JAMA*. 2002;288:3008–3013.
- Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Aufderheide TP, Rea T, Lowe R, Brown T, Dreyer J, Davis D, Idris A, Stiell I; Resuscitation Outcomes Consortium Investigators. Regional variation in out-of-hospital cardiac arrest incidence and outcome. *JAMA*. 2008;300:1423–1431. doi: 10.1001/jama.300.12.1423.
- Myerburg RJ, Halperin H, Egan DA, et al. Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshop. *Circulation*. 2013;128:2532–2541. doi: 10.1161/CIRCULATIONAHA.113.004490.
- Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. The incidence of sudden cardiac death in the general population. *J Clin Epidemiol*. 2004;57:98–102. doi: 10.1016/S0895-4356(03)00210-5.
- Kuisma M, Repo J, Alaspää A. The incidence of out-of-hospital ventricular fibrillation in Helsinki, Finland, from 1994 to 1999. *Lancet*. 2001;358:473–474. doi: 10.1016/S0140-6736(01)05634-3.
- Krahn AD, Connolly SJ, Roberts RS, Gent M; ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. *Am Heart J*. 2004;147:837–840. doi: 10.1016/j.ahj.2003.12.017.
- Iwami T, Hiraide A, Nakanishi N, Hayashi Y, Nishiuchi T, Yukioka H, Yoshiya I, Sugimoto H. Age and sex analyses of out-of-hospital cardiac arrest in Osaka, Japan. *Resuscitation*. 2003;57:145–152.
- Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. *Am Heart J*. 1998;136:205–212. doi: 10.1053/hj.1998.v136.90226.
- Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, Maggioni AP, Carson PE, Swedberg K, Levy WC. Important differences in mode of

- death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. *Circulation*. 2012;126:2402–2407. doi: 10.1161/CIRCULATIONAHA.111.069245.
40. Wissenberg M, Hansen CM, Folke F, Lippert FK, Weeke P, Karlsson L, Rajan S, Søndergaard KB, Kragholm K, Christensen EF, Nielsen SL, Køber L, Gislason GH, Torp-Pedersen C. Survival after out-of-hospital cardiac arrest in relation to sex: a nationwide registry-based study. *Resuscitation*. 2014;85:1212–1218. doi: 10.1016/j.resuscitation.2014.06.008.
 41. Akahane M, Ogawa T, Koike S, Tanabe S, Horiguchi H, Mizoguchi T, Yasunaga H, Imamura T. The effects of sex on out-of-hospital cardiac arrest outcomes. *Am J Med*. 2011;124:325–333. doi: 10.1016/j.amjmed.2010.10.020.
 42. Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, Barrett J. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. *N Engl J Med*. 1993;329:600–606. doi: 10.1056/NEJM199308263290902.
 43. Cowie MR, Fahrenbruch CE, Cobb LA, Hallstrom AP. Out-of-hospital cardiac arrest: racial differences in outcome in Seattle. *Am J Public Health*. 1993;83:955–959.
 44. Bertoia ML, Allison MA, Manson JE, Freiberg MS, Kuller LH, Solomon AJ, Limacher MC, Johnson KC, Curb JD, Wassertheil-Smolter S, Eaton CB. Risk factors for sudden cardiac death in post-menopausal women. *J Am Coll Cardiol*. 2012;60:2674–2682. doi: 10.1016/j.jacc.2012.09.031.
 45. Okin PM, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB. Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. *Heart Rhythm*. 2012;9:531–537. doi: 10.1016/j.hrthm.2011.11.008.
 46. Shah KS, Shah AS, Bhopal R. Systematic review and meta-analysis of out-of-hospital cardiac arrest and race or ethnicity: black US populations fare worse. *Eur J Prev Cardiol*. 2014;21:619–638. doi: 10.1177/2047487312451815.
 47. Teodorescu C, Reinier K, Dervan C, Uy-Evanado A, Samara M, Mariani R, Gunson K, Jui J, Chugh SS. Factors associated with pulseless electric activity versus ventricular fibrillation: the Oregon sudden unexpected death study. *Circulation*. 2010;122:2116–2122. doi: 10.1161/CIRCULATIONAHA.110.966333.
 48. Chan PS, Nichol G, Krumholz HM, Spertus JA, Jones PG, Peterson ED, Rathore SS, Nallamothu BK; American Heart Association National Registry of Cardiopulmonary Resuscitation (NRCPR) Investigators. Racial differences in survival after in-hospital cardiac arrest. *JAMA*. 2009;302:1195–1201. doi: 10.1001/jama.2009.1340.
 49. Sasson C, Magid DJ, Chan P, Root ED, McNally BF, Kellermann AL, Haukoos JS; CARES Surveillance Group. Association of neighborhood characteristics with bystander-initiated CPR. *N Engl J Med*. 2012;367:1607–1615. doi: 10.1056/NEJMoa1110700.
 50. Willey JZ, Rodriguez CJ, Moon YP, Paik MC, Di Tullio MR, Homma S, Sacco RL, Elkind MS. Coronary death and myocardial infarction among Hispanics in the Northern Manhattan Study: exploring the Hispanic paradox. *Ann Epidemiol*. 2012;22:303–309. doi: 10.1016/j.annepidem.2012.02.014.
 51. Gillum RF. Sudden cardiac death in Hispanic Americans and African Americans. *Am J Public Health*. 1997;87:1461–1466.
 52. Steinhaus DA, Vittinghoff E, Moffatt E, Hart AP, Ursell P, Tseng ZH. Characteristics of sudden arrhythmic death in a diverse, urban community. *Am Heart J*. 2012;163:125–131. doi: 10.1016/j.ahj.2011.09.016.
 53. Maruyama M, Ohira T, Imano H, Kitamura A, Kiyama M, Okada T, Maeda K, Yamagishi K, Noda H, Ishikawa Y, Shimamoto T, Iso H. Trends in sudden cardiac death and its risk factors in Japan from 1981 to 2005: The circulatory risk in communities study (circs). *BMJ open*. 2012;2:e000573.
 54. SPAIN DM, BRADESS VA, MOHR C. Coronary atherosclerosis as a cause of unexpected and unexplained death. An autopsy study from 1949–1959. *JAMA*. 1960;174:384–388.
 55. Albert CM, McGovern BA, Newell JB, Ruskin JN. Sex differences in cardiac arrest survivors. *Circulation*. 1996;93:1170–1176.
 56. Burke AP, Farb A, Pestaner J, Malcom GT, Zieske A, Kutys R, Smialek J, Virmani R. Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. *Circulation*. 2002;105:419–424.
 57. Nagata M, Ninomiya T, Doi Y, Hata J, Ikeda F, Mukai N, Tsuruya K, Oda Y, Kitazono T, Kiyohara Y. Temporal trends in sudden unexpected death in a general population: the Hisayama study. *Am Heart J*. 2013;165:932–938.e1. doi: 10.1016/j.ahj.2013.02.028.
 58. Priori SG, Borggrefe M, Camm AJ, Hauer RN, Klein H, Kuck KH, Schwartz PJ, Touboul P, Wellens HJ. Unexplained cardiac arrest. The need for a prospective registry. *Eur Heart J*. 1992;13:1445–1446.
 59. Chugh SS, Chung K, Zheng ZJ, John B, Titus JL. Cardiac pathologic findings reveal a high rate of sudden cardiac death of undetermined etiology in younger women. *Am Heart J*. 2003;146:635–639. doi: 10.1016/S0002-8703(03)00323-5.
 60. Murakoshi N, Aonuma K. Epidemiology of arrhythmias and sudden cardiac death in Asia. *Circ J*. 2013;77:2419–2431.
 61. Kaltman JR, Thompson PD, Lantos J, et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. *Circulation*. 2011;123:1911–1918. doi: 10.1161/CIRCULATIONAHA.110.017228.
 62. Greene HL. Sudden arrhythmic cardiac death—mechanisms, resuscitation and classification: the Seattle perspective. *Am J Cardiol*. 1990;65:4B–12B.
 63. Eisenberg MS, Copass MK, Hallstrom AP, Blake B, Bergner L, Short FA, Cobb LA. Treatment of out-of-hospital cardiac arrests with rapid defibrillation by emergency medical technicians. *N Engl J Med*. 1980;302:1379–1383. doi: 10.1056/NEJM198006193022502.
 64. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. *Circulation*. 1999;99:1978–1983.
 65. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. *Circulation*. 1995;91:1749–1756.
 66. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. *Acta Diabetol*. 2010;47(Suppl 1):161–168. doi: 10.1007/s00592-009-0157-9.
 67. Junttila MJ, Barthel P, Myerburg RJ, Mäkilä TH, Bauer A, Ulm K, Kiviniemi A, Tulppo M, Perkiömäki JS, Schmidt G, Huikuri HV. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. *Heart Rhythm*. 2010;7:1396–1403. doi: 10.1016/j.hrthm.2010.07.031.
 68. Deo R, Vittinghoff E, Lin F, Tseng ZH, Hulley SB, Shlipak MG. Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease. *Arch Intern Med*. 2011;171:1703–1709. doi: 10.1001/archinternmed.2011.328.
 69. Mayet J, Shahi M, Foale RA, Poulter NR, Sever PS, McG Thom SA. Racial differences in cardiac structure and function in essential hypertension. *BMJ*. 1994;308:1011–1014.
 70. Vlietstra RE, Kronmal RA, Oberman A, Frye RL, Killip T 3rd. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. Report from the CASS registry. *JAMA*. 1986;255:1023–1027.
 71. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A, Behar S, Reicher-Reiss H; Bezafibrate Infarction Prevention Study Group. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. *Arch Intern Med*. 2003;163:2301–2305. doi: 10.1001/archinte.163.19.2301.
 72. Sandhu RK, Jimenez MC, Chiuev SE, Fitzgerald KC, Kenfield SA, Tedrow UB, Albert CM. Smoking, smoking cessation, and risk of sudden cardiac death in women. *Circ Arrhythm Electrophysiol*. 2012;5:1091–1097. doi: 10.1161/CIRCEP.112.975219.
 73. Rahimi K, Majoni W, Merhi A, Emberson J. Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. *Eur Heart J*. 2012;33:1571–1581. doi: 10.1093/eurheartj/ehs005.
 74. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, Arbogast P, Raghunathan TE, Cobb LA. Family history as a risk factor for primary cardiac arrest. *Circulation*. 1998;97:155–160.
 75. Dekker LR, Bezzina CR, Henriques JP, Tanck MW, Koch KT, Alings MW, Arnold AE, de Boer MJ, Gorgels AP, Michels HR, Verkerk A, Verheugt FW, Zijlstra F, Wilde AA. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. *Circulation*. 2006;114:1140–1145. doi: 10.1161/CIRCULATIONAHA.105.606145.
 76. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. *Circulation*. 2006;114:1462–1467. doi: 10.1161/CIRCULATIONAHA.106.624593.
 77. Jabbari R, Engstrom T, Glinge C, et al. Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: A nationwide study in Denmark. *J Am Heart Assoc*. 2014. In press.
 78. Bezzina CR, Pazoki R, Bardai A, et al. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation

- in acute myocardial infarction. *Nat Genet.* 2010;42:688–691. doi: 10.1038/ng.623.
79. Arking DE, Junttila MJ, Goyette P, et al. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. *PLoS Genet.* 2011;7:e1002158. doi: 10.1371/journal.pgen.1002158.
 80. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. *JAMA.* 1995;274:1363–1367.
 81. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. *JAMA.* 1998;279:23–28.
 82. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS; Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. *Circulation.* 2003;107:1372–1377.
 83. Chiuve SE, Rimm EB, Sandhu RK, Bernstein AM, Rexrode KM, Manson JE, Willett WC, Albert CM. Dietary fat quality and risk of sudden cardiac death in women. *Am J Clin Nutr.* 2012;96:498–507.
 84. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med.* 2002;346:1113–1118. doi: 10.1056/NEJMoa012918.
 85. Leaf A, Kang XJ, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. *Circulation.* 2003;107:2646–2652. doi: 10.1161/01.CIR.0000069566.78305.33.
 86. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the gissi-prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. *Lancet.* 1999;354:447–455.
 87. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. *N Engl J Med.* 2010;363:2015–2026. doi: 10.1056/NEJMoa1003603.
 88. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation.* 2010;122:2152–2159. doi: 10.1161/CIRCULATIONAHA.110.948562.
 89. Chiuve SE, Krongold EC, Januzzi JL Jr, Gantzer ML, Albert CM. Plasma and dietary magnesium and risk of sudden cardiac death in women. *Am J Clin Nutr.* 2011;93:253–260. doi: 10.3945/ajcn.110.002253.
 90. Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, Folsom AR. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J.* 2010;160:464–470. doi: 10.1016/j.ahj.2010.06.012.
 91. Zarraga IG, Schwarz ER. Impact of dietary patterns and interventions on cardiovascular health. *Circulation.* 2006;114:961–973. doi: 10.1161/CIRCULATIONAHA.105.603910.
 92. Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, Albert CM. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. *JAMA.* 2011;306:62–69. doi: 10.1001/jama.2011.907.
 93. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhauser ML, Tinker LF, Van Horn L, Waring ME, Li W, Shikany JM, Eaton CB. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. *Am J Clin Nutr.* 2014;99:344–351. doi: 10.3945/ajcn.112.056135.
 94. Albert CM, Manson JE, Cook NR, Ajani UA, Gaziano JM, Hennekens CH. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. *Circulation.* 1999;100:944–950.
 95. Chiuve SE, Rimm EB, Mukamal KJ, Rexrode KM, Stampfer MJ, Manson JE, Albert CM. Light-to-moderate alcohol consumption and risk of sudden cardiac death in women. *Heart Rhythm.* 2010;7:1374–1380. doi: 10.1016/j.hrthm.2010.05.035.
 96. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhauser ML, Freiberg MS, Allison MA, Safford MM, Li W, Mossavar-Rahmani Y, Rosal MC, Eaton CB. Long-term alcohol and caffeine intake and risk of sudden cardiac death in women. *Am J Clin Nutr.* 2013;97:1356–1363. doi: 10.3945/ajcn.112.044248.
 97. Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. *Br Heart J.* 1992;68:443–448.
 98. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. *N Engl J Med.* 1993;329:1829–1834. doi: 10.1056/NEJM199312163292501.
 99. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. *Circulation.* 2013;128:2192–2201. doi: 10.1161/CIRCULATIONAHA.112.000491.
 100. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, Prineas R, Soliman EZ, Adabag S, Konety S, Folsom AR, Siscovick D, Alonso A. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. *JAMA Intern Med.* 2013;173:29–35. doi: 10.1001/2013.jamainternmed.744.
 101. Bardai A, Blom MT, van Hoeijen DA, van Deutekom HW, Brouwer HJ, Tan HL. Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large-scale population-based case-control study. *Circ Arrhythm Electrophysiol.* 2014;7:1033–1039. doi: 10.1161/CIRCEP.114.002094.
 102. Reinier K, Marijon E, Uy-Evanado A, Teodorescu C, Narayanan K, Chugh H, Gunson K, Jui J, Chugh SS. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. *JACC Heart Fail.* 2014;2:221–227. doi: 10.1016/j.jchf.2013.12.006.
 103. Collins AJ, Foley RN, Chavers B, et al. United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States. *Am J Kidney Dis.* 2012;59:A7, e1–420.
 104. Deo R, Sotoodehnia N, Katz R, Sarnak MJ, Fried LF, Chonchol M, Kestenbaum B, Psaty BM, Siscovick DS, Shlipak MG, Cystatin C and sudden cardiac death risk in the elderly. *Circ Cardiovasc Qual Outcomes.* 2010;3:159–164. doi: 10.1161/CIRCOUTCOMES.109.875369.
 105. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO, Herges RM, Howard DE, Somers VK. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. *J Am Coll Cardiol.* 2013;62:610–616. doi: 10.1016/j.jacc.2013.04.080.
 106. Bardai A, Blom MT, van Noord C, Verhamme KM, Sturkenboom MC, Tan HL. Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications. *Heart.* 2015;101:17–22. doi: 10.1136/heartjnl-2014-305664.
 107. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. *Am J Cardiol.* 1997;79:1512–1516.
 108. Willich SN, Goldberg RJ, Maclure M, Perriello L, Muller JE. Increased onset of sudden cardiac death in the first three hours after awakening. *Am J Cardiol.* 1992;70:65–68.
 109. Peckova M, Fahrenbruch CE, Cobb LA, Hallstrom AP. Weekly and seasonal variation in the incidence of cardiac arrests. *Am Heart J.* 1999;137:512–515.
 110. Arntz HR, Willich SN, Schreiber C, Brüggemann T, Stern R, Schultheiss HP. Diurnal, weekly and seasonal variation of sudden death. Population-based analysis of 24,061 consecutive cases. *Eur Heart J.* 2000;21:315–320. doi: 10.1053/euhj.1999.1739.
 111. Peters RW. Propranolol and the morning increase in sudden cardiac death: (the beta-blocker heart attack trial experience). *Am J Cardiol.* 1990;66:57G–59G.
 112. Gerber Y, Jacobsen SJ, Killian JM, Weston SA, Roger VL. Seasonality and daily weather conditions in relation to myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, 1979 to 2002. *J Am Coll Cardiol.* 2006;48:287–292. doi: 10.1016/j.jacc.2006.02.065.
 113. Chung FP, Li HR, Chong E, Pan CH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin WY, Shaw KP, Chen SA. Seasonal variation in the frequency of sudden cardiac death and ventricular tachyarrhythmia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: the effect of meteorological factors. *Heart Rhythm.* 2013;10:1859–1866. doi: 10.1016/j.hrthm.2013.09.069.
 114. Takigawa M, Noda T, Shimizu W, Miyamoto K, Okamura H, Satomi K, Suyama K, Aihara N, Kamakura S, Kurita T. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. *Heart Rhythm.* 2008;5:1523–1527. doi: 10.1016/j.hrthm.2008.08.022.
 115. Empena JP, Sauval P, Ducimetiere P, Tafflet M, Carli P, Jouven X. Increase in out-of-hospital cardiac arrest attended by the medical mobile intensive care units, but not myocardial infarction, during the 2003 heat wave in Paris, France. *Crit Care Med.* 2009;37:3079–3084. doi: 10.1097/CCM.0b013e3181b0868f.

116. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. *N Engl J Med*. 1984;311:874–877. doi: 10.1056/NEJM198410043111402.
117. Lemaitre RN, Siscovick DS, Raghunathan TE, Weinmann S, Arbogast P, Lin DY. Leisure-time physical activity and the risk of primary cardiac arrest. *Arch Intern Med*. 1999;159:686–690.
118. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. *JAMA*. 1982;248:1465–1477.
119. Whang W, Manson JE, Hu FB, Chae CU, Rexrode KM, Willett WC, Stampfer MJ, Albert CM. Physical exertion, exercise, and sudden cardiac death in women. *JAMA*. 2006;295:1399–1403. doi: 10.1001/jama.295.12.1399.
120. Kannel WB. Exercise and sudden death. *JAMA*. 1982;248:3143–3144.
121. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. *N Engl J Med*. 2000;343:1355–1361. doi: 10.1056/NEJM200011093431902.
122. Berdowski J, de Beus MF, Blom M, Bardai A, Bots ML, Doevendans PA, Grobbee DE, Tan HL, Tijssen JG, Koster RW, Mosterd A. Exercise-related out-of-hospital cardiac arrest in the general population: incidence and prognosis. *Eur Heart J*. 2013;34:3616–3623. doi: 10.1093/eurheartj/ehd401.
123. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier MC, Mustafic H, Toussaint JF, Desnos M, Rieu M, Benamer N, Le Heuzey JY, Empana JP, Jouven X. Sports-related sudden death in the general population. *Circulation*. 2011;124:672–681. doi: 10.1161/CIRCULATIONAHA.110.008979.
124. Kim JH, Malhotra R, Chiampras G, d'Hemecourt P, Troyanos C, Cianca J, Smith RN, Wang TJ, Roberts WO, Thompson PD, Baggish AL; Race Associated Cardiac Arrest Event Registry (RACER) Study Group. Cardiac arrest during long-distance running races. *N Engl J Med*. 2012;366:130–140. doi: 10.1056/NEJMoa1106468.
125. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC. Prospective study of phobic anxiety and risk of coronary heart disease in men. *Circulation*. 1994;89:1992–1997.
126. Albert CM, Chae CU, Rexrode KM, Manson JE, Kawachi I. Phobic anxiety and risk of coronary heart disease and sudden cardiac death among women. *Circulation*. 2005;111:480–487. doi: 10.1161/01.CIR.0000153813.64165.5D.
127. Empana JP, Jouven X, Lemaitre RN, Sotoodehnia N, Rea T, Raghunathan TE, Simon G, Siscovick DS. Clinical depression and risk of out-of-hospital cardiac arrest. *Arch Intern Med*. 2006;166:195–200. doi: 10.1001/archinte.166.2.195.
128. Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, Garan H, Albert CM. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. *J Am Coll Cardiol*. 2009;53:950–958. doi: 10.1016/j.jacc.2008.10.060.
129. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. *J Clin Psychiatry*. 2002;63(Suppl 9):5–11.
130. Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. *Clin Pharmacol Ther*. 2012;92:72–79. doi: 10.1038/clpt.2011.368.
131. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med*. 2009;360:225–235. doi: 10.1056/NEJMoa0806994.
132. Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. *N Engl J Med*. 1996;334:413–419. doi: 10.1056/NEJM199602153340701.
133. Meisel SR, Kutz I, Dayan KI, Pauzner H, Chetboun I, Arbel Y, David D. Effect of Iraqi missile war on incidence of acute myocardial infarction and sudden death in Israeli civilians. *Lancet*. 1991;338:660–661.
134. Kitamura T, Kiyohara K, Iwami T. The great east Japan earthquake and out-of-hospital cardiac arrest. *N Engl J Med*. 2013;369:2165–2167. doi: 10.1056/NEJMc1306058.
135. Niiyama M, Tanaka F, Nakajima S, Itoh T, Matsumoto T, Kawakami M, Naganuma Y, Omama S, Komatsu T, Onoda T, Sakata K, Ichikawa T, Nakamura M. Population-based incidence of sudden cardiac and unexpected death before and after the 2011 earthquake and tsunami in Iwate, northeast Japan. *J Am Heart Assoc*. 2014;3: e000798. doi: 10.1161/JAHA.114.000798.
136. Teng TH, Williams TA, Bremner A, Tohira H, Franklin P, Tonkin A, Jacobs I, Finn J. A systematic review of air pollution and incidence of out-of-hospital cardiac arrest. *J Epidemiol Community Health*. 2014;68:37–43. doi: 10.1136/jech-2013-203116.
137. Forastiere F, Stafoggia M, Picciotto S, Bellander T, D'Ippoliti D, Lanki T, von Klot S, Nyberg F, Paatero P, Peters A, Pekkanen J, Sunyer J, Perucci CA. A case-crossover analysis of out-of-hospital coronary deaths and air pollution in Rome, Italy. *Am J Respir Crit Care Med*. 2005;172:1549–1555. doi: 10.1164/rccm.200412-1726OC.
138. Raza A, Bellander T, Bero-Bedada G, Dahlquist M, Hollenberg J, Jonsson M, Lind T, Rosenqvist M, Svensson L, Ljungman PL. Short-term effects of air pollution on out-of-hospital cardiac arrest in Stockholm. *Eur Heart J*. 2014;35:861–868. doi: 10.1093/eurheartj/ehd489.
139. Silverman RA, Ito K, Freese J, Kaufman BJ, De Claro D, Braun J, Prezant DJ. Association of ambient fine particles with out-of-hospital cardiac arrests in New York City. *Am J Epidemiol*. 2010;172:917–923. doi: 10.1093/aje/kwq217.
140. Ensor KB, Raun LH, Persse D. A case-crossover analysis of out-of-hospital cardiac arrest and air pollution. *Circulation*. 2013;127:1192–1199. doi: 10.1161/CIRCULATIONAHA.113.000027.
141. Dennekamp M, Akram M, Abramson MJ, Tonkin A, Sim MR, Fridman M, Erbas B. Outdoor air pollution as a trigger for out-of-hospital cardiac arrests. *Epidemiology*. 2010;21:494–500. doi: 10.1097/EDE.0b013e3181e093db.
142. Levy D, Sheppard L, Checkoway H, Kaufman J, Lumley T, Koenig J, Siscovick D. A case-crossover analysis of particulate matter air pollution and out-of-hospital primary cardiac arrest. *Epidemiology*. 2001;12:193–199.
143. Wichmann J, Folke F, Torp-Pedersen C, Lippert F, Ketzl M, Ellermann T, Loft S. Out-of-hospital cardiac arrests and outdoor air pollution exposure in Copenhagen, Denmark. *PLoS One*. 2013;8:e53684. doi: 10.1371/journal.pone.0053684.
144. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, Anderson GL, Kaufman JD. Long-term exposure to air pollution and incidence of cardiovascular events in women. *N Engl J Med*. 2007;356:447–458. doi: 10.1056/NEJMoa054409.
145. Puett RC, Schwartz J, Hart JE, Yanosky JD, Speizer FE, Suh H, Paciorek CJ, Neas LM, Laden F. Chronic particulate exposure, mortality, and coronary heart disease in the nurses' health study. *Am J Epidemiol*. 2008;168:1161–1168. doi: 10.1093/aje/kwn232.
146. Hart JE, Chiuve SE, Laden F, Albert CM. Roadway proximity and risk of sudden cardiac death in women. *Circulation*. 2014;130:1474–1482. doi: 10.1161/CIRCULATIONAHA.114.011489.
147. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. *Am Heart J*. 1987;113:799–804.
148. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA; Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. *N Engl J Med*. 2005;352:2581–2588. doi: 10.1056/NEJMoa043938.
149. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. *JAMA*. 2008;300:2022–2029. doi: 10.1001/jama.2008.553.
150. Huikuri HV, Tapanainen JM, Lindgren K, Raatikainen P, Mäkilä TH, Juhani Airaksinen KE, Myerburg RJ. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. *J Am Coll Cardiol*. 2003;42:652–658.
151. ADELSON L, HOFFMAN W. Sudden death from coronary disease related to a lethal mechanism arising independently of vascular occlusion or myocardial damage. *JAMA*. 1961;176:129–135.
152. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. *Circulation*. 1995;92:1701–1709.
153. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. *N Engl J Med*. 1984;310:1137–1140. doi: 10.1056/NEJM198405033101801.
154. Kramer MC, Rittersma SZ, de Winter RJ, Ladich ER, Fowler DR, Liang YH, Kutys R, Carter-Monroe N, Kolodgie FD, van der Wal AC, Virmani R. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. *J Am Coll Cardiol*. 2010;55:122–132. doi: 10.1016/j.jacc.2009.09.007.
155. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N Engl J Med*. 1997;336:1276–1282. doi: 10.1056/NEJM199705103361802.
156. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. *Circulation*. 1998;97:2110–2116.

157. Poulleur AC, Barkoudah E, Uno H, et al; VALIANT Investigators. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. *Circulation*. 2010;122:597–602. doi: 10.1161/CIRCULATIONAHA.110.940619.
158. Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. *Circulation*. 1993;88:2953–2961.
159. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. *Circulation*. 1984;69:250–258.
160. Mäkilä TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP, Perkiömäki JS, Schmidt G, Huikuri HV. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. *Am J Cardiol*. 2006;97:480–484. doi: 10.1016/j.amjcard.2005.09.077.
161. Buxton AE. Risk stratification for sudden death in patients with coronary artery disease. *Heart Rhythm*. 2009;6:836–847. doi: 10.1016/j.hrthm.2009.02.016.
162. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML; MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). *J Am Coll Cardiol*. 2004;43:1459–1465. doi: 10.1016/j.jacc.2003.11.038.
163. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. 2002;346:877–883. doi: 10.1056/NEJMoa013474.
164. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. *Circulation*. 2009;120:2170–2176. doi: 10.1161/CIRCULATIONAHA.109.853689.
165. Epstein AE, DiMarco JP, Ellenbogen KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation*. 2008;117:e350–e408. doi: 10.1161/CIRCULATIONAHA.108.189742.
166. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. 2004;351:2481–2488. doi: 10.1056/NEJMoa041489.
167. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornejczak-Jach Z, Sredniawa B, Lupkovic G, Hofgärtner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J; IRIS Investigators. Defibrillator implantation early after myocardial infarction. *N Engl J Med*. 2009;361:1427–1436. doi: 10.1056/NEJMoa0901889.
168. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction \leq 30% should receive an implantable cardioverter-defibrillator. *Circulation*. 2005;111:2537–49; discussion 2537. doi: 10.1161/01.CIR.0000165057.88551.2C.
169. Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). *Circ Arrhythm Electrophysiol*. 2014;7:1084–1091.
170. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, McAnulty JH, Gunson K, Jui J, Chugh SS. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. *J Am Coll Cardiol*. 2006;47:1161–1166. doi: 10.1016/j.jacc.2005.11.045.
171. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med*. 1999;341:1882–1890. doi: 10.1056/NEJM199912163412503.
172. Lee DC, Goldberger JJ. CMR for sudden cardiac death risk stratification: are we there yet? *JACC Cardiovasc Imaging*. 2013;6:345–348. doi: 10.1016/j.jcmg.2012.12.006.
173. Exner DV, Kavanagh KM, Slawnych MP, et al; REFINe Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINe study. *J Am Coll Cardiol*. 2007;50:2275–2284. doi: 10.1016/j.jacc.2007.08.042.
174. Zaman S, Narayan A, Thiagalingam A, Sivagangabalan G, Thomas S, Ross DL, Kovoor P. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction. *Circulation*. 2014;129:848–854. doi: 10.1161/CIRCULATIONAHA.113.005146.
175. Zile MR, Gaasch WH, Anand IS, et al; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. *Circulation*. 2010;121:1393–1405. doi: 10.1161/CIRCULATIONAHA.109.909614.
176. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? *Eur J Heart Fail*. 2013;15:604–613. doi: 10.1093/eurjhf/hft062.
177. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation*. 2004;110:2180–2183. doi: 10.1161/01.CIR.0000144474.65922.AA.
178. Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. *J Cardiovasc Electrophysiol*. 2007;18:1231–1235. doi: 10.1111/j.1540-8167.2007.00957.x.
179. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail*. 2014;16:1175–1182. doi: 10.1002/ehf.172.
180. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. *Cardiovasc Res*. 2001;50:399–408.
181. Puranik R, Chow CK, Duflo JA, Kilborn MJ, McGuire MA. Sudden death in the young. *Heart Rhythm*. 2005;2:1277–1282. doi: 10.1016/j.hrthm.2005.09.008.
182. Ikeda T, Yusu S, Nakamura K, Yoshino H. Risk stratification for sudden cardiac death. *Circ J*. 2007;71(Suppl A):A106–A114.
183. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation*. 2006;113:1807–1816. doi: 10.1161/CIRCULATIONAHA.106.174287.
184. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2008;29:270–276. doi: 10.1093/eurheartj/ehm342.
185. Lakdawala NK, Winterfield JR, Funke BH. Dilated cardiomyopathy. *Circ Arrhythm Electrophysiol*. 2013;6:228–237. doi: 10.1161/CIRCEP.111.962050.
186. Epstein AE, DiMarco JP, Ellenbogen KA, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart

- Rhythm Society. *Circulation*. 2013;127:e283–e352. doi: 10.1161/CIR.0b013e318276ce9b.
187. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. 2005;352:225–237. doi: 10.1056/NEJMoa043399.
 188. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med*. 2004;350:2151–2158. doi: 10.1056/NEJMoa033088.
 189. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. *Europace*. 2010;12:1564–1570. doi: 10.1093/eurpace/euq329.
 190. Goldberger JJ, Subacius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. *J Am Coll Cardiol*. 2014;63:1879–1889. doi: 10.1016/j.jacc.2013.12.021.
 191. Gulati A, Jabbar A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. *JAMA*. 2013;309:896–908. doi: 10.1001/jama.2013.1363.
 192. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivetto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *J Am Coll Cardiol*. 2014;64:83–99. doi: 10.1016/j.jacc.2014.05.003.
 193. Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:2733–2779.
 194. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011;124:2761–2796. doi: 10.1161/CIR.0b013e318223e230.
 195. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J*. 2014;35:2010–2020. doi: 10.1093/eurheartj/ehu439.
 196. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation*. 2010;121:1533–1541. doi: 10.1161/CIRCULATIONAHA.108.840827.
 197. Murray B. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a review of molecular and clinical literature. *J Genet Couns*. 2012;21:494–504. doi: 10.1007/s10897-012-9497-7.
 198. den Haan AD, Tan BY, Zikusoka MN, Lladó LI, Jain R, Daly A, Tichnell C, James C, Amat-Alarcon N, Abraham T, Russell SD, Bluemke DA, Calkins H, Dalal D, Judge DP. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Cardiovasc Genet*. 2009;2:428–435. doi: 10.1161/CIRCGENETICS.109.858217.
 199. Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, Thivolet F, Chevalier P, Bouvagnet P. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. *Circulation*. 2003;108:3000–3005. doi: 10.1161/01.CIR.0000108396.65446.21.
 200. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, Ward D, Sen-Chowdhry S, Elliott PM, McKenna WJ. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. *Circulation*. 2011;123:2701–2709. doi: 10.1161/CIRCULATIONAHA.110.976936.
 201. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation*. 2003;108:3084–3091. doi: 10.1161/01.CIR.0000103130.33451.D2.
 202. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation*. 2004;110:1879–1884. doi: 10.1161/01.CIR.0000143375.93288.82.
 203. Lemola K, Bruckhorst C, Helfenstein U, Oechslin E, Jenni R, Duru F. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. *Heart*. 2005;91:1167–1172. doi: 10.1136/hrt.2004.038620.
 204. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. *J Am Coll Cardiol*. 2011;58:1485–1496. doi: 10.1016/j.jacc.2011.06.043.
 205. Loire R, Tabib A. [Unexpected sudden cardiac death. An evaluation of 1000 autopsies]. *Arch Mal Coeur Vaiss*. 1996;89:13–18.
 206. Groves P. Valve disease: Surgery of valve disease: late results and late complications. *Heart*. 2001;86:715–721.
 207. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. *Circulation*. 2005;111:3290–3295. doi: 10.1161/CIRCULATIONAHA.104.495903.
 208. Bhattacharya S, Hayward C, Pepper J, Senior R. Risk stratification in asymptomatic severe aortic stenosis: a critical appraisal. *Eur Heart J*. 2012;33:2377–2387. doi: 10.1093/eurheartj/ehs190.
 209. Kang DH, Park SJ, Rim JH, Yun SC, Kim DH, Song JM, Choo SJ, Park SW, Song JK, Lee JW, Park PW. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. *Circulation*. 2010;121:1502–1509. doi: 10.1161/CIRCULATIONAHA.109.909903.
 210. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. *Lancet*. 2005;365:507–518. doi: 10.1016/S0140-6736(05)17869-6.
 211. Sriram CS, Syed FF, Ferguson ME, Johnson JN, Enriquez-Sarano M, Cetta F, Cannon BC, Asirvatham SJ, Ackerman MJ. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. *J Am Coll Cardiol*. 2013;62:222–230. doi: 10.1016/j.jacc.2013.02.060.
 212. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. *J Am Coll Cardiol*. 2004;43:1137–1144. doi: 10.1016/j.jacc.2003.10.053.
 213. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT, Rowland E, Jeffery S, McKenna WJ. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. *Eur Heart J*. 2008;29:1670–1680. doi: 10.1093/eurheartj/ehn219.
 214. Papadakis M, Raju H, Behr ER, De Noronha SV, Spath N, Kouloubinis A, Sheppard MN, Sharma S. Sudden cardiac death with autopsy findings of uncertain significance: potential for erroneous interpretation. *Circ Arrhythm Electrophysiol*. 2013;6:588–596. doi: 10.1161/CIRCEP.113.000111.
 215. Hofman N, Tan HL, Alders M, Kolder I, de Haaij S, Mannens MM, Lombardi MP, Dit Deprez RH, van Langen I, Wilde AA. Yield of molecular and clinical testing for arrhythmia syndromes: report of 15 years' experience. *Circulation*. 2013;128:1513–1521. doi: 10.1161/CIRCULATIONAHA.112.000091.
 216. Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. *Am Heart J*. 1975;89:378–390.
 217. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. *Circulation*. 2011;124:2181–2184. doi: 10.1161/CIRCULATIONAHA.111.062182.
 218. Goldenberg I, Moss AJ. Long QT syndrome. *J Am Coll Cardiol*. 2008;51:2291–2300. doi: 10.1016/j.jacc.2008.02.068.
 219. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. *N Engl J Med*. 2003;348:1866–1874. doi: 10.1056/NEJMoa022147.
 220. Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital

- long QT syndrome. *Heart Rhythm*. 2004;1:276–283. doi: 10.1016/j.hrthm.2004.04.021.
221. Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. *J Am Coll Cardiol*. 2003;41:633–642.
 222. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. *Circulation*. 2009;120:1761–1767. doi: 10.1161/CIRCULATIONAHA.109.863209.
 223. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*. 2001;103:89–95.
 224. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *N Engl J Med*. 1998;339:960–965. doi: 10.1056/NEJM199810013391404.
 225. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. *Circulation*. 2007;115:2481–2489. doi: 10.1161/CIRCULATIONAHA.106.665406.
 226. Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type 2 long QT syndrome. *J Am Coll Cardiol*. 2009;54:2052–2062. doi: 10.1016/j.jacc.2009.08.028.
 227. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. *J Am Coll Cardiol*. 2004;44:117–125. doi: 10.1016/j.jacc.2004.03.043.
 228. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*. 2013;10:1932–1963. doi: 10.1016/j.hrthm.2013.05.014.
 229. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *J Am Coll Cardiol*. 1992;20:1391–1396.
 230. Gaw AC, Lee B, Gervacio-Domingo G, Antzelevitch C, Divinagrancia R, Jocano F Jr. Unraveling the Enigma of Bangungut: Is Sudden Unexplained Nocturnal Death Syndrome (SUNDS) in the Philippines a Disease Allelic to the Brugada Syndrome? *Philipp J Intern Med*. 2011;49:165–176.
 231. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA; Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation*. 2002;106:2514–2519.
 232. Shimizu W, Matsuo K, Kokubo Y, Satomi K, Kurita T, Noda T, Nagaya N, Suyama K, Aihara N, Kamakura S, Inamoto N, Akahoshi M, Tomoike H. Sex hormone and gender difference—role of testosterone on male predominance in Brugada syndrome. *J Cardiovasc Electrophysiol*. 2007;18:415–421. doi: 10.1111/j.1540-8167.2006.00743.x.
 233. Sakabe M, Fujiki A, Tani M, Nishida K, Mizumaki K, Inoue H. Proportion and prognosis of healthy people with coved or saddle-back type ST segment elevation in the right precordial leads during 10 years follow-up. *Eur Heart J*. 2003;24:1488–1493.
 234. Tsuji H, Sato T, Morisaki K, Iwasaka T. Prognosis of subjects with Brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination. *Am J Cardiol*. 2008;102:584–587. doi: 10.1016/j.amjcard.2008.04.066.
 235. Gervacio-Domingo G, Isidro J, Tirona J, Gabriel E, David G, Amarillo ML, Morales D, Dans A. The Brugada type 1 electrocardiographic pattern is common among Filipinos. *J Clin Epidemiol*. 2008;61:1067–1072. doi: 10.1016/j.jclinepi.2007.11.009.
 236. Ito H, Yano K, Chen R, He Q, Curb JD. The prevalence and prognosis of a Brugada-type electrocardiogram in a population of middle-aged Japanese-American men with follow-up of three decades. *Am J Med Sci*. 2006;331:25–29.
 237. Letsas KP, Gavrielatos G, Efremidis M, Kounas SP, Filippatos GS, Sideris A, Kardaras F. Prevalence of Brugada sign in a Greek tertiary hospital population. *Europace*. 2007;9:1077–1080. doi: 10.1093/europace/eum221.
 238. Gallagher MM, Forleo GB, Behr ER, Magliano G, De Luca L, Morgia V, De Liberato F, Romeo F. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. *Int J Cardiol*. 2008;130:44–48. doi: 10.1016/j.ijcard.2007.07.159.
 239. Pecini R, Cedergreen P, Theilade S, Haunsø S, Theilade J, Jensen GB. The prevalence and relevance of the Brugada-type electrocardiogram in the Danish general population: data from the Copenhagen City Heart Study. *Europace*. 2010;12:982–986. doi: 10.1093/europace/euq077.
 240. Patel SS, Anees S, Anees SS, Ferrick KJ. Prevalence of a Brugada pattern electrocardiogram in an urban population in the United States. *Pacing Clin Electrophysiol*. 2009;32:704–708. doi: 10.1111/j.1540-8159.2009.02354.x.
 241. Lee C, Soni A, Tate RB, Cuddy TE. The incidence and prognosis of Brugada electrocardiographic pattern in the Manitoba Follow-Up Study. *Can J Cardiol*. 2005;21:1286–1290.
 242. Kamakura S, Ohe T, Nakazawa K, et al; Brugada Syndrome Investigators in Japan. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1–V3. *Circ Arrhythm Electrophysiol*. 2009;2:495–503. doi: 10.1161/CIRCEP.108.816892.
 243. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. *Circulation*. 2010;121:635–643. doi: 10.1161/CIRCULATIONAHA.109.887026.
 244. Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, Calo L, Proclemer A, Marzali M, Rebollato L, Berton G, Coro L, Sitta N. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. *Eur Heart J*. 2011;32:169–176. doi: 10.1093/eurheartj/ehq381.
 245. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. *Circulation*. 1995;91:1512–1519.
 246. Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N, Lupoglazoff JM, Klug D, Maury P, Messali A, Guicheney P, Leenhardt A. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. *Europace*. 2012;14:1344–1351. doi: 10.1093/europace/eus031.
 247. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. *Circulation*. 2009;119:2426–2434. doi: 10.1161/CIRCULATIONAHA.108.829267.
 248. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation*. 2002;106:69–74.
 249. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. *Heart*. 2003;89:66–70.
 250. Swan H, Piippo K, Viitasalo M, Heikkilä P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L. Arrhythmic disorder mapped to chromosome 1q42–q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. *J Am Coll Cardiol*. 1999;34:2035–2042.
 251. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nat Med*. 2009;15:380–383. doi: 10.1038/nm.1942.
 252. FENICHEL NN. A long term study of concave RS-T elevation—a normal variant of the electrocardiogram. *Angiology*. 1962;13:360–366.
 253. Klatsky AL, Oehm R, Cooper RA, Udaltsova N, Armstrong MA. The early repolarization normal variant electrocardiogram: correlates and consequences. *Am J Med*. 2003;115:171–177.
 254. Haïssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. *N Engl J Med*. 2008;358:2016–2023. doi: 10.1056/NEJMoa071968.
 255. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, Halkin A, Steinvil A, Heller K, Glikson M, Katz A, Viskin S. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. *J Am Coll Cardiol*. 2008;52:1231–1238. doi: 10.1016/j.jacc.2008.07.010.
 256. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, Reunanen A, Huikuri HV. Long-term outcome associated with early repolarization on electrocardiography. *N Engl J Med*. 2009;361:2529–2537. doi: 10.1056/NEJMoa0907589.

257. Sinner MF, Reinhard W, Müller M, et al. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/KORA). *PLoS Med*. 2010;7:e1000314. doi: 10.1371/journal.pmed.1000314.
258. Olson KA, Viera AJ, Soliman EZ, Crow RS, Rosamond WD. Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. *Eur Heart J*. 2011;32:3098–3106. doi: 10.1093/eurheartj/ehr264.
259. Ilkhanoff L, Soliman EZ, Prineas RJ, Walsh JA 3rd, Ning H, Liu K, Carr JJ, Jacobs DR Jr, Lloyd-Jones DM. Clinical characteristics and outcomes associated with the natural history of early repolarization in a young, biracial cohort followed to middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Circ Arrhythm Electrophysiol*. 2014;7:392–399. doi: 10.1161/CIRCEP.113.000874.
260. Haruta D, Matsuo K, Tsuneto A, Ichimaru S, Hida A, Sera N, Imaizumi M, Nakashima E, Maemura K, Akahoshi M. Incidence and prognostic value of early repolarization pattern in the 12-lead electrocardiogram. *Circulation*. 2011;123:2931–2937. doi: 10.1161/CIRCULATIONAHA.110.006460.
261. Hisamatsu T, Ohkubo T, Miura K, Yamamoto T, Fujiyoshi A, Miyagawa N, Kadota A, Takashima N, Nagasawa SY, Kita Y, Murakami Y, Okayama A, Horie M, Okamura T, Ueshima H; NIPPON DATA90 Research Group. Association between J-point elevation and death from coronary artery disease—15-year follow up of the NIPPON DATA90. *Circ J*. 2013;77:1260–1266.
262. Noseworthy PA, Tikkanen JT, Porthan K, Oikarinen L, Pietilä A, Harald K, Peloso GM, Merchant FM, Jula A, Väänänen H, Hwang SJ, O'Donnell CJ, Salomaa V, Newton-Cheh C, Huikuri HV. The early repolarization pattern in the general population: clinical correlates and heritability. *J Am Coll Cardiol*. 2011;57:2284–2289. doi: 10.1016/j.jacc.2011.04.003.
263. Tikkanen JT, Junttila MJ, Anttonen O, Aro AL, Luttinen S, Kerola T, Sager SJ, Rissanen HA, Myerburg RJ, Reunanen A, Huikuri HV. Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome. *Circulation*. 2011;123:2666–2673. doi: 10.1161/CIRCULATIONAHA.110.014068.
264. Junttila MJ, Raatikainen MJP, Karjalainen J, Kauma H, Kesaniemi YA, Huikuri HV. Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. *Eur Heart J*. 2004;25:874–878.
265. Sinner MF, Pfeufer A, Perz S, Schulze-Bahr E, Monnig G, Eckardt L, Beckmann BM, Wichmann HE, Breithardt G, Steinbeck G, Fabritz L, Kaab S, Kirchhof P. Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. *Europace*. 2009;11:1338–1344.
266. Yamakawa Y, Ishikawa T, Uchino K, Mochida Y, Ebina T, Sumita S, Kobayashi T, Matsushita K, Matsumoto K, Ohkusu Y, Nishizawa T, Takigiku K, Iwamoto M, Kimura K, Umemura S. Prevalence of right bundle-branch block and right precordial ST-segment elevation (Brugada-type electrocardiogram) in Japanese children. *Circ J*. 2004;68:275–279.
267. Oe H, Takagi M, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Yoshiyama M, Nishimoto M, Tanaka K, Yoshikawa J. Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese population. *Pacing Clin Electrophysiol*. 2005;28:549–554.
268. Rollin A, Maury P, Bongard V, Sacher F, Delay M, Duparc A, Mondoly P, Carrié D, Ferrières J, Ruidavets JB. Prevalence, prognosis, and identification of the malignant form of early repolarization pattern in a population-based study. *Am J Cardiol*. 2012;110:1302–1308.
269. Uberoi A, MD, Jain NA, Perez M, Weinkopff A, Ashley E, Hadley D, Turakhia MP, Froelicher V. Early repolarization in an ambulatory clinical population. *Circulation*. 2011;124:2208–2214.